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Abstract
Due to their central role in normal cellular physiology, the activity of protein kinases is tightly
regulated and their aberrant activation can lead to cancer. Chronic myelogenous leukemia
(CML) is a blood cancer characterized by unregulated growth of myeloid cells caused by a
fusion protein, Bcr-Abl, a constitutively active form of the Abelson tyrosine kinase (Abl). While
treatment with drugs targeting the ATP binding pocket of Abl leads to durable therapeutic
responses, the development of drug resistance remains a major clinical problem. Targeting
additional sites on kinases outside the conserved ATP pocket is thought to be a promising
strategy to overcome drug resistance.
We hypothesized that protein-interacting domains such as SH2 act as allosteric regulator
of kinase activity and conformation. This project aimed at understanding the molecular
mechanisms underlying regulation of Abl kinases via the SH2-kinase allosteric interface as
well as developing a screening strategy for small-molecules disrupters of this interface. I
used recombinant Abl tyrosine kinases and conformation-speciﬁc kinase inhibitors to analyse
changes in conformation and phosphorylation that occur after Abl activation. I could show
that the Abl SH2-kinase interface enabled trans-phosphorylation of the activation loop and
disruption of the SH2–kinase interaction abolished its phosphorylation. To determine the
sufﬁciency of targeting the SH2-kinase interface for Bcr-Abl inhibition, high-afﬁnity mono-
bodies targeting the kinase-binding surface of the Abl SH2 were developed in collaboration
with the laboratory of Shohei Koide and their effects tested. The new monobodies inhibited
Bcr-Abl kinase activity in vitro and in cells, and induced cell death in a CML cell line. We
further used one of the monobodies to develop a screening assay based on the Homogeneous
Time Resolved Fluorescence (HTRF) principle. We sucessfully showed that some speciﬁc
donor/acceptor combinations could serve as a basis for high-throughput screening.
Finally, we have studied allosteric regulation of several other cytoplasmic tyrosine kinases
with an emphasis on the Btk kinase. We showed that the Btk kinase was strongly dependent
on its SH2 domain for activation loop autophosphorylation, a feature that was also observed
in transfected mammalian cells. The long-term goal is to identify new allosteric regulations in
oncogenic cytoplasmic tyrosine kinases that will help developing new types of therapeutics
for hematological malignancies or solid tumors.
Keywords: Allosteric regulation, cytoplasmic tyrosine kinases, Abl kinase, autophosphoryla-
tion, monobodies, cancer, chronic myeloid leukemia.
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Résumé
En raison de leur rôle central dans la physiologie cellulaire, l’activité des protéines kinases
est étroitement régulée et leur activation aberrante est souvent impliquée dans la formation
de cancers. La Leucémie Myéloïde Chronique (CML) est un cancer du sang caractérisé par
une croissance non régulée des cellules myéloïdes. Cette croissance est due à une protéine
de fusion, Bcr-Abl, une forme constitutivement active de la tyrosine kinase Abelson (Abl).
Bien que le traitement avec des médicaments ciblant le site de liaison à l’ATP de la kinase
Abl conduit à des réponses thérapeutiques durables, le développement de résistances aux
médicaments reste un problème clinique majeur. Le ciblage de nouveaux sites, en dehors de
la poche de liaison à l’ATP, peut être une stratégie prometteuse pour surmonter la résistance
aux médicaments.
Nous avons émis l’hypothèse que les domaines de liaisons tels que les domaines SH2 ou
SH3 peuvent agir comme régulateur allostérique de l’activité kinase. Ce projet consiste à
comprendre les mécanismes moléculaires sous-jacents qui régulent la kinase Abl via l’in-
terface formée entre les domaines SH2 et kinase ainsi qu’en l’élaboration d’une stratégie
de screening permettant de découvrir des molécules perturbatrices de cette interface. J’ai
puriﬁé des mutants de la protéine Abl et ai utilisé des inhibiteurs spéciﬁques permettant
d’analyser la phosphorylation se produisant après l’activation d’Abl. J’ai pu montrer que
l’interface SH2-kinase d’Abl favorise la trans-phosphorylation de la boucle d’activation, un
élément clé pour l’activation d’Abl. La perturbation de cette interface empêche l’activation de
la kinase Abl. Pour déterminer si empêcher la formation de l’interface SH2-kinase peut inhiber
la protéine Bcr-Abl, des monobodies de haute afﬁnité ciblant l’interface ont été développés
en collaboration avec le laboratoire de Shohei Koide. Ces nouveaux monobodies ont inhibé
l’activité de la kinase Bcr-Abl in vitro et dans des cellules, et ont induit la mort cellulaire dans
une lignée dérivée de patients atteints de CML. Nous avons également utilisé un des mono-
bodies pour développer un screening basé sur le principe de ’Homogeneous Time Resolved
Fluorescence’(HTRF). Nous avons montré avec succès que certaines combinaisons spéciﬁques
de donneur/accepteur peuvent servir de base pour un screening à haut débit.
Enﬁn, nous avons étudié la régulation allostérique de plusieurs autres tyrosines kinases
cytoplasmiques et plus spécialement la kinase Btk. Nous avons montré que la kinase Btk était
fortement dépendante de son domaine SH2 pour phosphoryler sa boucle d’activation, une
observation conﬁrmée dans des cellules de mammifères. L’objectif à long terme est d’identiﬁer
vii
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de nouvelles façons de cibler les protéines kinases impliquées dans des hémopathies malignes
ou des tumeurs solides.
Mot-clés : Régulation allostérique, tyrosines kinases cytoplasmiques, kinase Abl, autophos-
phorylation, monobodies, cancer, leucémie myéloide chronique.
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1 Introduction
1.1 Protein tyrosine kinases
Protein phosphorylation is a key biochemical hallmark of metazoans mediated by essential
enzymes called protein kinases. By transfering a γ-phosphate of ATP and covalently attaching
it to serine, threonine or tyrosine residues, kinases allow for quick and speciﬁc propagation of
cellular signals.
The human genome encodes 518 kinases (Manning et al., 2002), of which 90 are tyrosine
kinases. The protein tyrosine kinase family is divided into two types of proteins: trans-
membrane receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (CTKs), which
are then further grouped into subfamilies based on protein sequence homology.
The CTK family consists of 34 known members, all containing a central core kinase domain
and several non-catalytic domains (Robinson et al., 2002) (ﬁgure 1.1).
1.1.1 Non-catalytic domains
Non-catalytic domains are very diverse and can have important roles in cellular localization
or binding of downstream targets (Neet and Hunter, 1996). For example domains such as SH2
which bind phospho-tyrosines allow tight spatial regulation and speciﬁc binding of CTKs to
tyrosine-phosphorylated protein targets. The 121 SH2 domains (Machida et al., 2007) are well
conserved among proteins and their role have been extensively studied. In several CTKs, it
has been shown that they promote the so-called processive phosphorylation in which the
kinase binds pre-phosphorylated substrate ("primed" substrate) via its SH2 and catalyzes other
phosphorylation events before dissociating (Patwardhan and Miller, 2007). This phenomenom
is usually required for efﬁcient phosphorylation of protein substrates in kinases such as Abl
(Mayer et al., 1995) or Src (Scott and Miller, 2000). SH3 domains bind proline-rich motifs
and are as well important for recognizing cellular substrates, protein regulation and can even
enhance SH2-dependent processive phosphorylation (Pellicena and Miller, 2001).
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Figure 1.1 – Structural organisation overview of cytoplasmic tyrosine kinases.
Non-catalytic domain names are the following. SH2/SH3: Src-homology 2/3; PH: Pleckstrin-
homology; TH: Tec-homology; F-BAR: Bin-Amphiphysin-Rvs; SAM: Sterile-α-motif; CRIB:
Cdc42/Rac-interactive-binding-motif; FERM: 4.1 protein-ezrin-radixin-moesin; FAT: focal-
adhesion-targeting.
Other domains such as PH and FERM allow proteins to be localized to the membrane through
binding to phospho-lipids. They are usually essential for protein kinase activity and path-
way activation. For example plasma membrane localization of Btk protein is an essential
step for its role in B-cell activation and mutations in its PH domain can lead to X-linked
agammaglobulinemia (XLA) (Mauno et al., 1995).
Finally some of these domains are implicated in protein-protein interaction complexes (SAM,
CRIB). The CRIB domain in Ack kinase is indispensible for its interaction with the activated
form of Cdc42 GTPase to promote cell survival and multiplication (Kato-Stankiewicz et al.,
2001).
1.1.2 Kinase domain
The kinase domain is a highly conserved domain of about 300 amino-acids that transfers
phosphates to the hydroxyl-group of protein substrates. The structure of a kinase domain can
be sub-divided into two domains, or lobes (ﬁgure 1.2). The smaller N-terminal lobe, or N-lobe,
is composed of ﬁve stranded β-sheets and a prominent α helix called helix αC. The C-lobe is
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larger and mostly α-helical. ATP binds in a deep cleft located between these two lobes just
beneath a conserved glycine-rich loop (Cox et al., 1994). This loop coordinates ATP binding
via backbone interactions. Optimal phosphate transfer requires a precise sequence of spatial
arrangements of several residues located in the glycine-rich (gly-rich) loop, the αC helix and
the catalytic loop (HRD motif) (Huse and Kuriyan, 2002).
The C-lobe contains a very ﬂexible loop called activation loop. The activation loop has the ca-
pacity to undergo large conformational changes and is switching between a closed ("inactive")
conformation to an open ("active") conformation usually stabilized by phosphorylation of a
particular tyrosine residue in the loop (ﬁgure 1.2). In the open conformation the loop serves
as a platform for further substrate binding (Huse and Kuriyan, 2002).
aC helix
Glyc-rich 
loop
Activation loop
Phospho-tyr
N-lobe
C-lobe
Activation loop
Glyc-rich 
loop
aC helix
(b) Active(a) Inactive
Figure 1.2 – Typical structural organization of an active and inactive kinase domain.
(a) Cartoon representation of the inactive Abl kinase domain (PDB: 1IEP). (b) Cartoon presenta-
tion of active Lck kinase (PDB: 3LCK). N- and C- lobes are shown in blue an green respectively.
αC helix is shown in yellow. The activation loop (in light blue) switches between a closed
conformation (a) to an open conformation (b) where in most tyrosine kinases a tyrosine
residue is phosphorylated (phospho-tyr).
1.1.3 Implication of cytoplasmic tyrosine kinases in cancer
Due to their important roles in most aspects of cellular signaling, deregulation of CTKs activity
by point mutations, translocations, deletions or duplications, can result in over-activation
leading to cancer and other malignancies (Hubbard and Till (2000), Blume-Jensen and Hunter
(2001)).
The discovery of the Src protein in 1978 (Levinson et al., 1978) led not only to the uncovering of
tyrosine phosphorylation but also to the fact that protein kinases can have high transforming
ability. Src kinase is now an established oncogene that can aberrantly activate pathways
downstream of several RTKs. Src-family kinases (SFKs) have now well documented roles in
tumor progression and invasion. SFKs can have various roles in malignancies such as breast,
colorectal, prostate or lung cancer (Zhang and Yu, 2012).
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Many CTKs can be oncogenic drivers and passengers in various tumor types. Btk kinase,
essential for the development of B-cells, is an important drug target in chronic lymphocytic
leukemia and multiple myeloma. Similarly the B-cell Syk kinase is a therapeutic target in
non-Hodgkin’s lymphoma, or B-cell lymphomas. Brk kinase is ampliﬁed in subtypes of breast
cancer and mutations in Ack1 were identiﬁed in lung adenocarcinoma and ovarian carcinoma.
One of the paradigmatic representative of tyrosine kinases in cancer is c-Abl, which has an
essential implication in chronic myeloid leukemia.
1.2 c-Abl: a prototypic cytoplasmic tyrosine kinase
1.2.1 The Abl kinase family
c-Abl is a member of the CTK family and the prototype of a sub-family which includes two
members: c-Abl (ABL1) and its only paralogue Arg (ABL2, Abl related gene). Members of this
family are highly conserved throughout the metazoans and ubiquitously expressed. c-Abl is
localised at various sites in the cell including cytoplasm, nucleus but also mitochondria and
endoplasmic reticulum (Wetzler et al., 1993).
The human ABL1 gene can give rise to two alternative splicing transcripts: ABL1a and ABL1b
(Renshaw et al., 1988). The 1b splicing variant is myristoylated at the N-terminus (glycine 2)
whereas the 1a variant is 19 amino acids shorter and not myristoylated (ﬁgure 1.4).
The two variants of c-Abl show a modular organization similar to that of members of Src
family. They are characterized by a core tyrosine kinase domain that is preceded by SH2 and
SH3 domains. Unique to c-Abl is the downstream region also called the ‘last exon region’.
This region is a long carboxy-terminal extension containing nuclear localization signals (NLS)
that allows the protein to shuttle between nucleus and cytoplasm (Taagepera et al., 1998).
This region is also implied in the interaction with F-actin (Hantschel et al., 2005) and has
proline-rich motifs that function as binding sites for SH3 domains of adaptor proteins.
Cellular processes in which c-Abl is implicated range from regulation of cell growth and
survival, oxidative stress and DNA damage response to actin dynamics and cell migration
(Van Etten, 1999).
1.2.2 c-Abl regulation via autoinhibition and phosphorylation
Because of its involvement in many cellular processes essential for cell viability, the tyrosine
kinase activity of c-Abl is very tightly controlled and c-Abl is mostly inactive in cells (Van Et-
ten (1999), Smith et al. (1999)). Structural and biochemical studies have revealed multiple
autoinhibitory mechanisms. The autoinhibition relies on a complex set of intramolecular
interactions that keep the kinase in a closed and inactive conformation. The myristoyl group
in the cap region has a major role in the autoinhibition of c-Abl 1b (Hantschel et al., 2003).
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The myristate can nestle into a deep hydrophobic pocket in the kinase C-lobe thus forcing
the SH2 and SH3 domains to dock against the kinase lobes and keeping the kinase inactive
(Pluk et al. (2002), Nagar et al. (2003)) (ﬁgure 1.3). In this so-called "clamped" conformation,
the SH2 domain forms a tight protein-protein interface with the C-lobe of the kinase domain
via a network of hydrogen bonds. The SH3 domain participates in this autoinhibited confor-
mation by interacting with the SH2-kinase linker region that can adopt a poly-proline type II
conformation. Conversion of inactive c-Abl to its active form requires the disruption of these
intramolecular interactions (Hantschel et al., 2003). SH2 and SH3 binders can provoke a disas-
sembling of the clamp conformation and dislodge the myristate. Following the breakdown
of inhibitory contacts, the full activation of Abl kinase is achieved by the phosphorylation
of several tyrosine residues. The non-myristoylated form c-Abl 1a seems to be regulated by
intramolecular interactions as well, however, the elements that replace the function of the
myristate remain to be determined.
SH3
SH2
Kinase domain
Myristate
SH2
SH3
Kinase domain
(a) : Cartoon representation (b) : Surface representation
Myristate binding pocket
Figure 1.3 –Autoinhibited structure of Abl kinase. Autoinhibited conformation of ABL kinase
(PDB: 1OPK). Cartoon (a) and surface (b) representations are shown. Kinase domain, SH2 and
SH3 are shown in blue, green and yellow respectively. The myristate is shown with red spheres.
The SH2-kinase linker is shown in light pink. In this autoinhibited form, the SH2 and SH3
clamp against the kinase domain, locking the kinase in an inactive state.
As for many other tyrosine kinases, c-Abl activity in cells is heavily dependent on phosphory-
lation sites located throughout the protein. It has been shown that the mutation of tyrosine
245 (Y245) and tyrosine 412 (Y412) to phenylalanine prevents c-Abl from activation revealing
the important roles of these sites (Dorey et al., 2001). Phosphorylation of the Y245 in the SH2-
kinase domain linker could inhibit the docking of the SH3 domain, stabilizing the kinase in
the active conformation. This phosphorylation is coupled by a concomitant phosphorylation
of Y412 in the activation loop which stabilizes the loop in a conformation that is compatible
with substrate binding (Brasher and Van Etten, 2000). Due to its ability to act as a dominant
oncogene once deregulated, c-Abl is a medically important and long studied protein. Its
role has been extensively studied in a speciﬁc type of blood cancer called chronic myeloid
leukemia.
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1.3 Chronic myeloid leukemia and Bcr-Abl fusion protein
1.3.1 Chronic myeloid leukemia
In 1845, the pathologist John Hughes Bennett reported a case of spleen and liver hypertrophy
in which death took place from "blood suppuration" in the Edimburgh Medical Journal
(Bennett, 1845). Only a few weeks later, Rudolf Virchow in Berlin published a very similar case.
Although one cannot know for sure, these cases probably represented the ﬁrst descriptions of
the disease later known as chronic myeloid leukemia (CML).
CML is a form of leukemia characterized by the unregulated growth of predominantly myeloid
cells in the bone marrow and the accumulation of these cells in the blood and peripheral
organs. CML occurs in all age groups but most commonly after 50 years of age and accounts
for 15 % of adult leukemias (Jemal et al., 2010). CML displays three majors clinical phases
(Jabbour and Kantarjian, 2014). In most patients, the disease manifests as a long chronic
phase that shows an increased count of periphal blood myeloid progenitors but often remains
undiscovered for years. Upon progression patients enter the accelerated phase characterized
by splenomegaly and an increasing number of blast cells (immature cells). If left untreated the
disease progresses to a fatal blast crisis where hematopoietic differentiation is blocked and
blast cells accumulate in the bones and in the blood.
A real breakthrough in the ﬁeld was the discovery of an abnormally small chromosome in
cells from CML sick patients by cytogeneticists Peter Nowel and David Hungerford (Nowell
and Hungerford, 1960). Later named the Philadelphia chromosome, this discovery made
CML the ﬁrst cancer to be clearly linked to a genetic abnormality. Thirteen years later, Janet
Rowley showed that the Philadelphia chromosome was the result of a reciprocal translocation
between chromosomes 9 and 22. The Philadelphia translocation juxtaposes the ABL1 gene on
chromosome 9 with the breakpoint cluster region gene (BCR) on chromosome 22 leading to
the expression of the fusion protein called Bcr-Abl (Rowley, 1973). The resulting fusion protein
is a constitutively activated form of the Abl kinase contributing to cellular transformation.
1.3.2 Bcr-Abl: driver of chronic myeloid leukemia
In CML, the most common Bcr-Abl fusion is a protein of 210 kDa also known as Bcr-Abl p210.
Bcr-Abl p210 contains the whole c-Abl sequence except the N-terminal region, replaced by Bcr.
Absence of the N-terminal "cap" region prevents myristoylation of the protein and releases
c-Abl from autoinhibition (McWhirter and Wang, 1991)(ﬁgure 1.4).
It has also been shown that the Bcr contains a coiled-coiled domain that is essential for
leukemogenesis (McWhirter et al., 1993) . This domain induces Bcr-Abl oligomerization which
also disrupts c-Abl inhibition by inducing strong autophosphorylation of Abl critical tyrosine
residues. Not only the fusion with Bcr affects autoinhibitory mechanisms but it also allows
Bcr-Abl to activate many type of mitogenic signals.
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Figure 1.4 – Structural organization of c-Abl and Bcr-Abl. Upon translocation with Bcr, c-Abl
looses its cap region and thus cannot be myristoylated anymore and become constitutively
active. FABD: F-actin binding domain.
Via a plethora of interactors, Bcr-Abl activates proliferative and anti-apoptotic pathways such
as MAPK (Sanchez-Arevalo-Lobo et al., 2005) or PI3K-Akt (Skorski et al., 1997). Bcr-Abl has
even been shown to directly induce strong phosphorylation of STAT5, thereby activating it,
and completely by-passing the canonical JAK/STAT pathway (Hantschel et al., 2012). STAT5
activation is required for leukemegonesis (Ye et al., 2006) and one of the most critical pathway
for CML maintenance. STAT5 is know considered as a signalling hallmark of CML (Shuai et al.,
1996).
All these alterations result in a constitutive activation of multiple survival signals by the p210
oncoprotein that contributes to transformation and resistance to apoptosis. Importantly,
expression of Bcr-Abl alone is sufﬁcient for the transformation of hematopoietic stem cells,
leading to CML in humans and in a CML-like disorder in mice (Daley et al., 1990). The central
role of the Abl kinase in the pathophysiology of CML was a chance for the development of
molecular targeted therapies using highly speciﬁc Bcr-Abl tyrosine kinase inhibitors.
In the ﬁrst half of the 20th century, CML patients were predominantly treated with chemo-
therapy (Silver et al., 1999) until the introduction of recombinant interferon α (rIFNα) (Talpaz
et al., 1986) and allogenic stem cell transplantation (SCT) that both became standard-of-care
for CML patients (Beatty, 1997). The success of rIFNα was limited because less than 50%
of patients had signiﬁcant responses with most of the patients suffering from side-effects
(Homewood et al., 1997). Despite being a possible curative therapy, SCT suffered from high
mortality and morbidity rates (Doney et al. (1978), McGlave et al. (1981)).
The true revolution in CML treatment, and more generally in cancer research, was the intro-
duction in 2001 of the ﬁrst speciﬁc tyrosine kinase inhibitor called imatinib.
1.4 Targeted therapy and development of resistances
1.4.1 First-generation tyrosine kinase inhibitor: imatinib as the magic bullet?
Due to the highly conserved structure of the protein kinase domain of the 518 human kinases,
there were doubts that kinases could be targeted speciﬁcally.
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But early compounds, termed tyrphostins (short name for tyrosine phosphorylation inhibitors,
Yaish et al. (1988), Gazit et al. (1989)), could discriminate between serine/threonine and
tyrosine kinases.
In the late 1990s, a lead compound from a protein kinase C inhibitors screening was modiﬁed
and showed inhibition of a limited number of kinases in vitro: the Abl kinase and the receptor
tyrosine kinases KIT and PDGFR (Buchdunger et al. (1996), Druker et al. (1996)). Due to the
central role of Bcr-Abl kinase in CML, targeting of the Abl kinase domain has been further
followed-up. Medicinal chemistry optimization led to the development of imatinib (Capdeville
et al., 2002). The good tolerability and efﬁcacy in the phase I and II clinical trials led to the
approval of imatinib in 2001 by the US Food and Drug Administration (FDA) and shortly after
by the European Medicines Agency (EMA) under the name Gleevec (Druker et al., 2001).
Imatinib was then the ﬁrst kinase inhibitor and targeted therapy in cancer patients and
was thought to be the "magic bullet" against cancer. It has converted CML from a deadly
cancer to a chronic condition, in which most patients have a good quality-of-life. Today,
imatinib is used as the ﬁrst line therapy to treat CML patients in all disease phases as well
as for gastrointestinal stromal tumors (Heinrich et al., 2003) and a few other diseases. The
elucidation of the molecular mechanisms-of-action of imatinib has provided a solid basis for
the understanding of kinase inhibitor binding and has helped to identify key mechanisms by
which cancer cells may become resistant.
1.4.2 Structural mechanisms of imatinib binding
Imatinib lays at the interface between the N- and C-terminal lobes of the Abl kinase domain,
in the so-called hinge-region (Nagar et al. (2002), Schindler et al. (2000), ﬁgure 1.5). Its
binding site overlaps with the ATP binding and imatinib is therefore an ATP-competitive
inhibitor. Imatinib forms a number of interactions, especially hydrogen bonds, with both
the N- and C-lobes of the kinase domain. Drug binding induces a down folding of the Gly-
rich loop maintained by a water-mediated hydrogen bond between residues Y272 and N341
(ﬁgure 1.5). The ﬂexibility of the Gly-rich loop is important for the binding of imatinib as the
conformational changes of the loop increases surface complementarity with the drug.
Another important aspect is that imatinib mostly binds to the closed conformation of the Abl
activation loop. This binding mode is referred as type 2 kinase inhibition, which is character-
ized by an inactive conformation of the activation loop that folds into the active site occluding
substrate binding (ﬁgure 1.5). More importantly, residue D381 in the conserved Asp-Phe-Gly-
(DFG) motif, located at the beginning of the activation loop and being essential for the coordi-
nation of ATP, is found displaced from its inward facing orientation in active kinases toward
the “out” conformation. This not only prevents kinase activity but the concomitant inward
rotation of residue F401 of the DFG motif exposes a hydrophobic region directly adjacent to
the ATP site that is recognized by type 2 inhibitors (hydrophobic site 1, ﬁgure 1.5). Another
hydrophobic region that is not contacted by ATP is exploited by the imatinib molecule and
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contributes to its high binding speciﬁcity (hydrophobic site 2, ﬁgure 1.5). Access to this site is
controlled by the so-called gatekeeper residue, which is a threonine (residue T334) in Bcr-Abl
and which forms a hydrogen bond with imatinib.
Despite the great clinical efﬁcacy, the success story of imatinib has been hampered by the
emergence of drug resistances (Lamontanara et al., 2012).
Activation loop
Folds into the 
substrate binding 
site as in inactive 
kinases.
Y412
Hydrophobic 
site 1
Hydrophobic 
site 2
F401
Thr-334: gatekeeper residue
Makes an important hydrogen bond with Imatinib.
DFG-out conformation
Displacement of F401 exposes 
hydrophobic site 1.
Y272
N341
Gly-rich loop
Folds down over imatinib. 
D400
aC-helix
Figure 1.5 – Structural features of imatinib binding to the Abl kinase. A cartoon representa-
tion of the crystal structure of the Abl kinase domain bound to imatinib (red sticks) is shown
(PDB: 1IEP). Imatinib binds an inactive conformation of the Abl kinase with the activation
loop (green) occluding the substrate binding site and the DFG motif displaced in the out
conformation, exposing hydrophobic site 1. The binding of imatinib induces a down folding
of the Gly-rich loop (yellow). The gatekeeper residue (T334, purple) makes an important
hydrogen bond with imatinib and controls access to the hydrophobic site 2. Figure modiﬁed
from Lamontanara et al. (2012).
1.4.3 Development of resistances to imatinib
Just before the introduction of imatinib to the market, scientists began to observe a number
of leukemic derived cells lines resistant to the drug (Mahon et al., 2000). This was rapidly
followed by clinical resistance in patients (Gorre et al., 2001) and led the efforts to understand
the underlying mechanisms. Patients that failed to achieve responses at predeﬁned time
points were described as primarily resistant to therapy, and those who lost previously ob-
tained regression were considered as secondarily resistant and developed so-called acquired
resistances.
Many types of resistance mechanisms to imatinib have been studied. While some Bcr-Abl
independent resistances were observed such as upregulation of drug efﬂux (Illmer et al.,
2004), most patients relapse because of Bcr-Abl dependent mechanisms such as Bcr-Abl
overexpression (Gadzicki et al., 2005) or most commonly, mutations in the Abl kinase domain.
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The major mutational hotspot is the gatekeeper residue of Bcr-Abl and the T334I mutation
was the ﬁrst identiﬁed in relapsed CML patients (Gorre et al., 2001). The absence of the
hydroxyl group normally provided by the side chain of residue T334 (ﬁgure 1.5) prevents
formation of a hydrogen bond with imatinib. In addition, isoleucine is a bulkier residue and
therefore sterically hinders imatinib binding. This strongly increases the IC50 of imatinib to
concentrations exceeding the plasma concentrations that can be reached in patients.
The Gly-rich loop is a second hotspot for mutations in Bcr-Abl. Mutations such as Y272H/F
and E274K/V are most commonly observed (Soverini et al., 2012). The Y272H/F mutation
results in the loss of the hydrogen bond that normally keeps the Gly-rich loop locking imatinib
in its binding site (Roumiantsev et al., 2002) (ﬁgure 1.5). In comparison to the T334I mutation,
the degree of resistance of Gly-rich loop mutations is relatively mild. Typically less than a
10-fold increase in IC50 relative to unmutated Bcr-Abl is observed. But this change is sufﬁcient
to restore Bcr-Abl kinase activity in imatinib-treated patients carrying these mutations.
A third mutation hot-spot is the activation loop, with residue H415 being the most frequently
mutated. The crystal structure of the Abl kinase domain carrying the H415P mutation displays
the active conformation of the activation loop to which imatinib binds less readily (Young
et al., 2006). In line with this observation, the H415P mutation was shown to strongly activate
Abl kinase activity providing a possible explanation for the observed imatinib resistance
(Sherbenou et al., 2010). Thus, activation loop mutations, although not contacting imatinib
directly, shift the equilibrium towards the active conformation of the kinase domain, which
weakens imatinib binding.
Drug resistance is one of the main driver in continuing research and development of new
inhibitors. This has led to the approval of several second- and third-generation inhbitors.
1.4.4 Second- and third-generation Abl inhibitors
Because most resistant point mutations only mildly decrease imatinib efﬁciency (not more
than 10-fold, O’Hare et al. (2005)), increasing the plasma drug concentration seemed a possible
way to deal with resistance. Higher doses of imatinib in the initial phase of therapy were shown
to increase the depth and kinetic of responses, which is associated with improved survival
(Hehlmann et al., 2011). The downside of this approach is the increased toxicity observed
at higher imatinib doses and only mutants conferring rather mild (2-3-fold increased IC50)
resistance are likely targetable using this approach. Therefore, efforts have concentrated on
the development of new drugs that target Bcr-Abl carrying point mutations in the kinase
domain directly.
Three second-generation inhibitors have been approved for the treatment of imatinib-resistant
or -intolerant patients: nilotinib, dasatinib and bosutinib. Nilotinib and dasatinib have also
been approved for front-line therapies.
Nilotinib was developed based on the structure of the Abl-imatinib complex and inhibits
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most of the common mutations, although some Gly-rich loop mutations are only partially
inhibited. The drug retains the main scaffold of imatinib and binds very similarly to the
inactive conformation of the Abl tyrosine kinase (type 2 inhibitor, ﬁgure 1.6). Nilotinib showed
a better ﬁt to the kinase (ﬁgure 1.6) with a less stringent binding allowing for higher ﬂexibility
and explaining its efﬁciency for resistant mutants (Weisberg et al., 2007). Nilotinib is very
speciﬁc and mainly targets the same kinases as imatinib; Abl1/2, KIT, PDGFRA/B and DDR1/2
(Rix et al. (2007), Hantschel et al. (2008)).
For dasatinib, the mechanism of inhibition differs drastically from imatinib and nilotinib. The
crystal structure of the dasatinib-Abl complex showed that the drug binds the active form
of the Abl kinase domain (activation loop opened, type 1 inhibitor)(ﬁgure 1.6, Tokarski et al.
(2006)). Dasatinib occupies a different part of the cleft between the N- and C-lobe. While the
central core overlaps with imatinib, the rest of the molecule extends in the opposite direction,
pointing toward the solvent. The drug does not occupy the hydrophobic site 2 (ﬁgures 1.5 and
1.6) and therefore does not need a DFG-out conformation to bind. In contrast to imatinib, no
conformational changes of the Gly-rich loop were observed. This allows dasatinib to bind with
less stringent conformational requirements, which contributes to its high efﬁcacy. Dasatinib
has a much broader target spectrum than imatinib and nilotinib. It potently inhibits all Src
kinases, most Tec kinases, almost the entire EphA/B family but also serine-threonine kinases
in addition to the kinases inhibited by imatinib and nilotinib.
Bosutinib has very similar properties to dasatinib in terms of inhibition type (type 1), potency
(low nanomolar IC50) and spectrum of kinase domain mutations being inhibited (Golas et al.
(2003), Puttini et al. (2006)). Bosutinib has an even broader target spectrum than dasatinib
(Bantscheff et al. (2007), Remsing Rix et al. (2009)).
All second-generation inhibitors remained inefﬁcient at inhibiting the common point mu-
tation T334I (gatekeeper mutation). This prompted the development of third-generation
inhibitors speciﬁcally targeting the gatekeeper mutation. So far, one such inhibitor has been
approved: ponatinib.
Ponatinib is a type 2 inhibitor that efﬁciently targets the T334I mutation (O’Hare et al., 2009).
It binds in a very similar manner as imatinib and nilotinib, but an ethinyl linkage (C-C triple
bond) allows ponatinib to avoid sterical clashes with the T334I mutant. Ponatinib has medium
speciﬁcity targeting Src kinases but also receptor tyrosine kinases, such as KIT, PDGFR, VEGF,
and the FGFR family members. Its good efﬁcacy in patients carrying the T334I mutation
(Cortes et al., 2013) has led to the FDA-approval of ponatinib in December 2012.
One year following approval, the FDA requested to suspend drug marketing as more than 25%
patients suffered from severe artherial or venous thrombosis (Valent et al., 2014). In January
2014, ponatinib was reintroduced in the market but for a limited number of patients: the ones
harbouring the T334I mutation, or patients for whom no other inhibitors are indicated or
tolerated. These safety issues greatly hampered the use of the only current inhibitor on the
market that can target the T334I mutation.
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Figure 1.6 – Structural comparison of the Abl kinase in complex with imatinib, nilotinib
and dasatinib. For each inhibitor its name, structure and generation is shown. The complexes
with Abl kinase are displayed using surface representation of the kinase (blue) and respective
inhibitors (red). Finally binding type (1 or 2) is shown with cartoon representation of the
kinase (blue) with activation loop in brown and inhibitors with a stick representation (red).
1.5 Current challenges in targeting kinases
After the milestone approval of imatinib in 2001, an exploding amount of therapeutic kinase
inhibitors have been developped and approved over the last decade (ﬁgure 1.7). As of April
2015, 28 kinase inhibitors have been approved (Wu et al., 2015) with an average number of 1
per year between 2000 and 2009 increasing to more than 3 per year between 2010 and 2015
(ﬁgure 1.7). Most of the approved inhibitors target tyrosine kinases (ﬁgure 1.7) and 26 out of the
28 approved drugs have been developed for cancer therapy showing the important implication
of the tyrosine kinase group in targeted cancer therapy. Despite the drastic progress in kinase-
based drug discovery over the past 15 years, the ﬁeld of classical kinase inhibitor is facing
several challenges.
First, only a small-subset of kinases are targeted. This clear bias is illustrated by the fact that
three groups of tyrosine kinases - namely Bcr-Abl, ErbBs and VEFGRs - account for 18 out of
the 28 approved drugs.
Second, for most of the current treatments using ATP-competitors, patients develop resis-
tances through points mutations, usually in the kinase domain, decreasing drastically drug
efﬁciency. As for Abl, it is common to observe mutations of the gatekeeper residue and for
12
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example lung adenocarcinomas patients that were treated with geﬁtinib or erlotinib acquired
resistance due to the T790M mutation in EGFR (Pao et al., 2005), which corresponds to the
T334 gatekeeper residue position in Bcr-Abl.
Finally, developing highly speciﬁc ATP-competitors has been discouraging and an inherent
problem with kinase inhibitors. This fact is explained by the high sequence similarity and
folding among kinase domains. In fact, almost all current inhibitors have dozens of off-target
kinases (Davis et al. (2011), Anastassiadis et al. (2011)) leading to compromised tolerability
and sometimes life-threatening side-effects (as observed with ponatinib).
A more effective approach would be to simultaneously or alternatingly target sites outside
the ATP-pocket, commonly named allosteric sites (Fang et al., 2012). These sites need to be
critical for the regulation of kinase activity or the recruitment of substrates to be viable drug
targets. Hence, a deep understanding of allosteric kinase regulatory mechanisms is necessary
to exploit exclusive structural and biochemical features of particular oncogenic kinases
Year
Nu
m
be
r o
f F
DA
 a
pp
ro
ve
d 
dr
ug
s
20
00
20
01
20
03
20
04
20
05
20
06
20
07
20
09
20
11
20
12
20
13
20
14
20
15
0
10
20
30 Total number of kinase inhibitorsNumber of tyrosine kinase inhibitors
1
4
9
23
20
28
23
Figure 1.7 – Number of kinase inhibitors approved over the last 15 years. Red bars represent
tyrosine kinase inhibitors and blue bars all types of kinase inhibitors. Based on Wu et al. (2015).
1.6 Targeting allosteric regulatory sites in Abl
1.6.1 Targeting the myristate pocket
As described in Section 1.2.2, the Abl 1b kinase isoform harbours a N-terminal myristoylation
that is accommodated in a deep allosteric binding pocket in the tyrosine kinase domain.
Because the N-terminal myristoylation region is missing in Bcr-Abl fusion protein, it was
suggested that the myristate binding pocket could be targeted using compound mimicking
myristate effects and push the protein to its autoinhibited form (Hantschel et al., 2003).
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Figure 1.8 – GNF-2 induced bending of αI-helix in Abl kinase. Binding of GNF-2 to the
myristate pocket in Abl kinase C-lobe (blue, PDB: 3K5V) induces a sharp bend of helix αI
as compared to activated Abl (cyan, PDB: 2QOH). This bending mimicks the binding of the
myristate in the same pocket
This pocket has indeed been successfully targeted by compounds such as GNF-2 in Bcr-
Abl dependent cell lines and in vitro. Binding experiments using recombinant Abl kinase
conﬁrmed that GNF-2 was acting as a non-ATP-competitive kinase inhibitor (Adrián et al.,
2006). As supported by mutagenesis studies and kinase assays, functional inhibition by GNF-2
requires the involvement of the SH3 and SH2 domain to induce the autoinhibited clamped
conformation (Adrián et al., 2006).
Despite its very good potency against certain imatinib resistant mutations, this compound
failed to inhibit the T334I mutation (Adrián et al., 2006). Interestingly, it has shown efﬁcacy
against this mutation when combined with classical ATP competitive inhibitors (Khateb et al.,
2012). The crystal structure of the Abl kinase domain bound to both GNF-2 and imatinib
has been recently obtained (Zhang et al., 2010). Once bound to the myristate pocket, mostly
through hydrophobic interactions, GNF-2 induces a sharp bending of the C-terminal helix
αI (ﬁgure 1.8) also observed when a myristate was bound and facilitating the stabilization of
an inhibited conformation. Oddly, the binding of imatinib to the kinase domain in complex
GNF-2 seemed very similar to the kinase bound to imatinib only and this could not explain
the synergestic effects observed in cells.
To shed light onwhy such combination of amyristate pocket binderwith classical ATP competi-
tors could efﬁciently inhibit the gatekeeper mutant, hydrogen-exchange mass-spectrometry
has been carried out using a coumpound with improved pharmacokinetic properties termed
GNF-5 (Zhang et al., 2010). In addition to changes in the myristate pocket, changes in peptides
near the ATP-binding site were also seen, implying that binding of GNF-5 affected the ATP-
site. This showed that allosteric targeting of Abl kinase can cause dynamic perturbations to
residues in the ATP-binding site and provided a mechanism by which synergistic interactions
14
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between these two sites could occur. Recent studies have shown that binding of imatinib to
Abl kinase leads to an unexpected open conformation of the multidomain SH3-SH2-kinase
c-Abl core. The combination of imatinib with the allosteric inhibitor GNF-5 restored the
closed, inactivated state (Skora et al., 2013).
1.6.2 Targeting the SH2-kinase interface
Although the canonical function of the SH2 domain is the binding of phosphotyrosine residues,
additional regulatory roles of the SH2 domain in CTKs have been recently discovered. Upon
Abl kinase activation, the SH2 domain has been shown to bind to the tip of the kinase N-lobe
in diverse structural studies, forming a tight SH2-kinase interface (ﬁgure 1.9) (Grebien et al.,
2011). The interaction, mostly hydrophobic, is maintained through the critical I164 residue
located in the SH2. Importantly, none of the SH2 residues implied in this interaction are
involved in phosphotyrosine binding.
The ﬁrst evidence that the SH2-kinase interface observed in active Abl inﬂuences leukemo-
genesis was recently provided in a study of the Bcr-Abl SH2-kinase interface. In this study,
a mutation disrupting the SH2-kinase interface, the isoleucine 164 to glutamate mutation
(I164E), reduced catalytic activity and autophosphorylation sites (Grebien et al., 2011). On
the contrary, the T231R mutation stabilizing the interaction between the SH2 and the kinase
via formation of an additional ionic interaction with glutamate 294 (ﬁgure 1.9) drastically
increased Bcr-Abl autophosphorylation ability. Of note, the T231R mutation was observed in a
patient resistant to imatinib (Sherbenou et al., 2010), highliting the possible importance of this
new mechanism of action for Bcr-Abl activity and inhibition. Interestingly, the I164E mutation
also sensitized Bcr-Abl kinase resistant mutants (e.g, the T334I mutation) to imatinib and
other Abl kinase inhibitors. More importantly disruption of the SH2-kinase domain interface
using the I164E mutation completely abolished leukemia formation in a mouse bone marrow
transplantion model (Grebien et al., 2011).
The authors then generated single-domain binding proteins based on the ﬁbronectin type
III domain (FN3), termed monobodies, able to bind the Abl SH2 domain. Monobodies are
small proteins of 10 kDa that can bind with high afﬁnity and speciﬁty to their targets making
them robust alternatives to antibodies (Koide et al., 1998). Monobodies are stables and easily
expressed in E. coli and do not harbour any dissulﬁde bonds, making them functional even in
reducing environments such as cytoplasm. They can readily be used as genetically encoded
intracellular inhibitors, and can be usefull tools for in vitro studies using mammalian cells or
in solution. Monobodies are usually highly speciﬁc and achieve afﬁnity in the low nanomolar
range and have been proven to be excellent tools for dissecting signalling networks and ﬁnding
new possible therapeutic targets (Sha et al., 2013). The binding of a monobody to the Abl
SH2 domain, could indeed interfere with the formation of the interface, indicating that this
interface could be a pharmacologically tractable target. The monobody also inhibited Bcr-Abl
kinase activity (Grebien et al., 2011).
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Figure 1.9 – Abl SH2-kinase unit in active conformation. Upon activation, the SH2 (green)
binds at the tip of the kinase N-lobe (blue) forming a tight SH2-kinase interface (PDB: 1OPL).
The isoleucine 164 (I164) in the SH2 is a crucial residue and its mutation disrupts the interac-
tion between the two domains. Mutation of threonine 231 (T231) to arginine makes an ionic
interaction with glutamate 294 (E294) and increases the interaction.
Interestingly the SH2 orientation toward the kinase domain was similar between Abl, Fes
and Csk, and always sitting on the top of the kinase N-lobe albeit with different orientations
(ﬁgure 1.10). The physiological relevance of this interface was more extensively studied in the
case of the Fes kinase (Filippakopoulos et al., 2008). A similar construct was obtained for Src
but showed little to no interactions between the SH2 and kinase domain (Cowan-Jacob et al.,
2005).
1.7 Aims of the work
Despite its importance in the development of leukemogenesis, the molecular mechanisms
underlying the Abl SH2-kinase interface are poorly characterized. With the development of
resistances against tyrosine kinase inhibitors and side-effects observed with some of them,
it is becoming evident that new type of regulatory sites should be found. My project aims at
understanding the regulation of Abl kinase via the SH2-kinase interface. Through this work we
would like to analyze the Abl SH2-kinase allosteric regulation using an in vitro recombinant
system and to further conﬁrm its therapeutic usage.
With the exception of a few kinases, little is known about the domain arrangements and con-
formations in active CTKs. Regulation of CTKs has not been studied in a deﬁned standardized
way through comparative analysis of enzymatic and structural characterization. Allosteric reg-
ulation in kinases might imply complex molecular re-wiring with long-range communications
that need to be further investigated. Understanding these mechanisms will pave the way to
the exploitation of regulatory secondary sites in kinases.
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Figure 1.10 – Structural overview of Abl, Fes, Csk and Src SH2/3-kinase units. Abl (PDB:
1OPL), Fes (PDB: 3BKB) and Csk (1K9A) display similar features where their SH2 domains
(green) sit on top of their kinase domains (blue) with different orientations. In Src (PDB: 1Y57),
little to no interaction is observed between the SH3/2 domain and the kinase.
The three major questions of my thesis are:
• Can we obtain highly pure and active recombinant Abl kinase constructs and recapitu-
late SH2-kinase regulation in vitro ? In that context several constructs harbouring point
mutations will be analyzed in order to better understand the molecular mechanisms
implied. This will also permit to shed light on the role and inﬂuence of phosphorylation
on the positive kinase regulation by the Abl SH2 domain.
• Can the Abl SH2-kinase be a possible therapeutic target ? I would like to conﬁrm the
importance of the Abl SH2-kinase interface as a possible therapeutic and targetable in-
terface with the help of monobodies and develop screening asssays for small-molecules
that could interfere with the formation of this interface.
• Is allosteric kinase activation via SH2, or other non-catalytic domains, a possible feature
of several other CTKs ? I would like to deﬁne a standardized way of studying multi-
domain constructs of CTKs in solution and in cells and to further establish the role of
possible allosteric mechanisms in concerned CTKs.
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2 Results
2.1 Characterizationof bacterially expressedAbl SH2-kinasedomain
unit proteins
2.1.1 Expression and puriﬁcation of recombinant Abl SH2-kinase
The detailed understanding of allosteric mechanisms in Abl kinase and the potential roles of
new allosteric protein-drug interactions demands a method for the production of proteins in
the milligram scale.
We have set-up an E.coli expression system that gave good yield, purity and kinase activity.
The protocol is based on the co-expression of different Abl kinase mutants with a tyrosine-
phosphatase named Yersinia Outer Phosphatase (YopH) (Seeliger et al., 2005). YopH is a
phosphatase essential for Yersinia virulence that has a very high non-speciﬁc tyrosine phos-
phatase activity (Bliska et al., 1991).
To conﬁrm that the protocol in place could give highly pure and stable recombinant Abl kinase,
the wild-type (WT) SH2-kinase domain (SH2-KD) unit was ﬁrst puriﬁed by nickel afﬁnity and
ion exchange chromatography. The Abl SH2-KD protein eluted with a gradient of imidazole in
a single peak (data not shown) and the pooled fractions were analyzed by SDS-PAGE (ﬁgure
2.1a). The major part of the protein contaminants was eliminated in the ﬂowthrough and
wash fractions (ﬁgure 2.1a). At this step, the main impurity was the YopH protein, which tends
to unspeciﬁcally bind Nickel afﬁnity resin despite the lack of His-tag.
Based on the strongly different pI, subsequent anion exchange chromatography on a MonoQ
column was used to remove the YopH contaminant. The YopH impurity was correctly elimi-
nated in the anion exchange ﬂowthrough (ﬁgure 2.1a). Abl SH2-KD was eluted with a linear
gradient of NaCl (0-350 mM). Only one major peak was observed (ﬁgure 2.1b) and the fractions
were pooled . The fraction contained pure SH2-kinase protein and almost no detectable phos-
phatase activity, as determined using an in vitro phosphatase assay (data not shown). Protein
identity was conﬁrmed by mass spectrometry and was in close agreement with the expected
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Figure 2.1 – Puriﬁcation and validation of the Abl SH2-KD purity and homogeneity.
(a) Coomassie staining of fraction collected at different steps of puriﬁcation. (b) Chro-
matogram of anion exchange showing a main peak for the Abl SH2-KD after NaCl elution. (c)
Gel ﬁltration coupled with a multi-angle light-scattering analysis of the Abl SH2–KD.
molecular mass (46681 Da for an expected weight of 46666 Da). No tyrosine phosphorylation
was detectable with mass spectrometry showing that the puriﬁcation workﬂow gives pure and
unphosphorylated Abl SH2-KD.
To conﬁrm monodispersity, we analyzed puriﬁed Abl SH2-KD using a gel ﬁltration coupled
to a Multi-Angle Light Scattering system (MALS). The Abl SH2-KD WT eluted as a single
monodisperse peak with a calculated mass of about 43 kDa (± 5 kDa) (ﬁgure 2.1c). Despite
MALS being a very sensitive technique to detect protein aggregation, none was found in the
recombinant protein preparation. Encouraged by the quality of the puriﬁed Abl SH2-KD WT, I
puriﬁed several Abl kinase mutants for biochemical and biophysical characterization.
2.1.2 Recombinant Abl SH2-KD unit recapitulates kinase regulation by the SH2
domain
Following the same protocol as for the Abl SH2-KD WT, I puriﬁed several Abl SH2-KD mutants
as well as Abl kinase domain only (KD).
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Figure 2.2 – Central Abl SH2-KD and KD mutants used in this study. (a) Schematic repre-
sentation of the central mutants used in this study. (b) Coomassie staining of 20 μg of the
puriﬁed mutants. Figure modiﬁed from Lamontanara et al. (2014).
The main mutants used in this study are the following (ﬁgure 2.2a):
• The I164E mutation in the SH2 domain predicted to decrease interaction with the KD
N-lobe and the T231R predicted to increase it (Grebien et al., 2011)
• The S173N mutant in the SH2 domain impaired in phospho-tyrosine binding
• Kinase-activity defective Abl KD and SH2-KD mutants via the D382N mutation
All of the mutants were obtained with very good purity (ﬁgure 2.2b) and were monomeric and
monodisperse (data not shown).
To conﬁrm that the recombinant proteins could recapitulate the role of the SH2 domain
observed in cells (Grebien et al., 2011), in vitro enzyme kinetic experiments using an optimal
Abl substrate peptide (Abltide) was performed. We observed an increase of the Abl SH2-KD
Vmax when compared with KD (ﬁgure 2.3a and table 2.1). As expected the I164E nulliﬁed the
increase whereas the T231R slightly increased the Vmax compared to Abl SH2-KD WT. The
phosphotyrosine binding deﬁcient S173N mutant had similar enzymatic properties to WT.
The far-ultraviolet circular dichroism spectra of SH2–KD WT and I164E were virtually identical,
indicating that the decrease in kinase activity was not due to protein unfolding or loss of
stability when the SH2-KD interface is disrupted (ﬁgure 2.3b).
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Figure 2.3 – Recombinant Abl SH2-KD recapitulates regulation via the SH2 domain. (a) Pu-
riﬁed Abl mutants were assayed for kinase activity against an optimal Abl peptide and the
kinetics ﬁtted using the Michaelis-Menten equation (n = 2). (b) Far-UV circular dichroism anal-
ysis of Abl SH2-KD WT and I164E showed no difference in folding upon interface disruption.
MRE: Mean Residue Ellipticity. Figure modiﬁed from Lamontanara et al. (2014).
Table 2.1 – Enzymatic kinetic parameters for Abl SH2-KD and KD mutants. Vmax and KM
values computed from ﬁgure 2.3a using Michaelis and Menten equation.
Constructs Vmax [nmole Pi min−1 μM−1] Km [μM]
KD ≈260 ≈4
SH2-KD ≈410 ≈5
SH2-KD I164E ≈260 ≈8
SH2-KD T231R ≈550 ≈8
SH2-KD S173N ≈400 ≈6
Despite the lack of tyrosine phosphorylation, the bacterially expressed Abl proteins exhibited
robust in vitro kinase activity, in line with the results of Abl KD puriﬁed from insect cells
(Schindler et al., 2000). This showed that previous observations on the allosteric role of the
SH2 domain in cells could be recapitulated in vitro with bacterially expressed Abl proteins.
2.1.3 SAXS reconstruction of the Abl SH2-KD unit
To conﬁrm that the structure of the Abl SH2-KD unit in solution was indeed the top-hat
conformationwhere the SH2domainwould sit on top of the kinase, we conducted Small-Angle-
X-ray Scattering (SAXS) reconstruction experiments in collaboration with Dmitri Svergun at
EMBL Hamburg. The SAXS revealed increasingly extended conformation in KD (Dmax = 70 Å)
to SH2-KD (Dmax = 95 Å) to SH2-KD I164E (Dmax = 110 Å) (ﬁgure 2.4a). The Abl SH2-KD and
KD Ab initio reconstructions revealed rigid structures that ﬁt very well the available crystal
structures (ﬁgure2.4b,c). These results indicated that the SH2 is indeed interacting with the
N-lobe of the KD in solution.
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For the SH2–KD I164E mutant, the data suggested signiﬁcant domain rearrangements, as
rigid body modelling using the available domain structures did not provide a satisfactory ﬁt.
Indeed, the Kratky plot (ﬁgure 2.4a) showed an increase in the ﬂexibility of the I164E mutant
because a shift from the expected peak was observed. Thus, the potential ﬂexibility of the
mutant and the scattering data was analysed in terms of co-existing conformer ensembles.
The selected ensembles that elucidated the conformational space of possible SH2 domain
positions with respect to the KD are displayed in ﬁgure 2.4c. The SH2 signiﬁcantly shifted
from its top-hat position conﬁrming the central role of the I164 residue in maintaining a tight
interaction with the tip of the KD.
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Figure 2.4 – Structural analysis of the Abl SH2-KD using SAXS. (a) P(r) distance distribution
functions (left panel) and normalized Kratky plots (right panel) are shown. The expected
peak (grey dashed line) represents the theoritical peak assuming an ideal guinier region of
a globular particule. (b,c) Ab initio reconstruction of Abl KD and SH2-KD super-imposed to
their crystal structures (PDB: 1OPL for KD and 1OPL molecule B for SH2-KD). (d) Flexible
characterization of the SH2-KD I164E mutant of three possible positions based on ensemble
optimization method. Figure modiﬁed from Lamontanara et al. (2014).
23
Chapter 2. Results
2.2 Abl SH2-KD autophosphorylation ability
2.2.1 Mapping of autophosphorylation sites
Active Abl is phosphorylated on several sites in cells and we sought to map these sites in
vitro to check for autophosphorylation sites. After incubation with excess ATP, we identiﬁed
phosphorylated sites using mass spectrometry. Among the 24 tyrosines present in the SH2-KD
protein, we found that 9 became phosphorylated (table 2.2 and ﬁgure 2.5). All identiﬁed
site were found highly annotated in the phosphosite repository (www.phosphosite.org) and
previously identiﬁed inmultiple phospho-proteomics data sets fromBcr-Abl expressing cancer
cell lines. These results showed that the Abl SH2-KD retained speciﬁcity in vitro because all
the sites found were also reported in cells. Two important regulatory sites were found to be
autophosphorylated: the tyrosines 412 and 245.
Table 2.2 – Identiﬁed in vitro autophosphorylation sites in the Abl SH2-KD.
The peptide counts, sequences of the identiﬁed phosphorylation peptides, locations and
Phosphosite.org record counts of mapped SH2–KD autophosphorylation sites are shown. The
phosphorylation site is denoted in bold on the peptide sequence.
Site
Peptide
count
Sequence Location
Phosphosite
record number
Y147 9 KHSWYHGPVSRN SH2 211
Y158 2 RNAAEYLLSSGINGSFLVRE SH2 57
Y204 3 KLYVSSESRF SH2 550
Y245 71 KRNKPTVYGVSPNYDKW SH2-kinase linker 314
Y272 14 KLGGGQYGEVYEGVWKK N-lobe, Gly-rich loop 287
Y276 8 KLGGGQYGEVYEGVWKK N-lobe, Gly-rich loop 338
Y283 4 KKYSLTVAVKT N-lobe 56
Y412 7 RLMGDTYTAHAGAKF C-lobe, activation loop 1714
Y432 3 KWTAPESLAYNKF C-lobe 160
2.2.2 The Abl SH2 is indispensible for activation loop autophosphorylation
Giving the importance of Abl phosphorylation for its activation, we analyzed the mechanisms
of autophosphorylation using unphosphorylated kinases. We incubated several Abl SH2-KD
mutants with excess ATP and monitored increase in total phosphotyrosine levels over-time
using a dot-blot assay system. Strikingly, the Abl KD was deﬁcient in autophosphorylation
(ﬁgure 2.6a), despite its robust activity toward an exogenous substrate (ﬁgures 2.3a). In
contrast, Abl SH2-KD showed rapid and robust increase in autophosphorylation that was
further potentiated via the T231R mutation. However, the I164E mutant showed a strong
decrease in autophosphorylation ability. The S173N mutant was not affected compared
to the WT protein, indicating that total Abl kinase autophosphorylation does not require
phospho-tyrosine binding of the SH2 (ﬁgure 2.6a-c).
24
2.2. Abl SH2-KD autophosphorylation ability
Kinase
domain
Y432
Y412
Y204Y147
SH2
domain
Y245
SH2-kinase
linker
Y272
Y276
Y283
Y158
Figure 2.5 – Mapping of autophosphorylated tyrosines in recombinant Abl SH2-KD. The
positions of phosphorylation sites mapped by mass-spectrometry after Abl SH2-KD autophos-
phorylation are shown as red sticks on the structure of the Abl SH2-KD (PDB: 1OPL molecule
B).
Next, we analyzed autophosphorylation ability at two important regulatory sites which are
tyrosine 245 (in the SH2-KD linker) and tyrosine 412 (in the activation loop). As reliable
phosphorylation site-speciﬁc antibodies are available for both sites we also used the dot-blot
system. Autophosphorylation of Y412 was strongly decreased in the I164E mutant (ﬁgure
2.6d-f); however the T231R mutant protein showed a strong increase in phosphorylation
kinetics at Y412 (ﬁgure 2.6d-f). In contrast disrupting (I164E) or enhancing (T231R) the SH2-
KD interface did not signiﬁcantly affect autophosphorylation ability at Y245 (ﬁgure 2.6g-i).
Notably autophosphorylation at Y245 seemed to precede Y412 because it began earlier and
showed a steeper incline (ﬁgure 2.7).
Thus, we tested possible interdependence of these two phosphorylation events using puriﬁed
Y245F and Y412F mutants. The two mutants exluded cross-reactivities of the phospho-speciﬁc
antibodies. The Y245F mutant showed decreased autophosphorylation kinetics at Y412 (ﬁgure
2.6d-f), however the ability of the Y412F to autophosphorylate at Y245 was unchanged (ﬁgure
2.6g-i). Prior Y245 phosphorylation could enhance Y412 phosphorylation by the binding
of phospho-Y245 to the Abl SH2 domain, therefore we also tested the S173N mutant, that
render the SH2 incapable of phospho-tyrosine binding. As expected, the S173N mutant was
autophosphorylated at Y245 with the same kinetic as WT (ﬁgure 2.6g-i). In contrast, the Y412
phosphorylation was strongly impaired by the S173N mutation (ﬁgure 2.6d-f).
These experiments showed that the Abl SH2-KD interface is one of the major determinants
that enables Abl autophosphorylation (Lamontanara et al., 2014).
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In the absence of the SH2-KD interaction, the Abl KD is defective in the autophosphorylation
of the activation loop (Y412). Of note, the observed effects are more pronounced than the
differences in Vmax for phosphorylation of a peptide substrate (ﬁgure 2.3). In addition the
autophosphorylation experiments were done in Abl concentration well below KM for substrate
peptides, meaning that the differences in activation loop phosphorylation are unlikely to be
due to differences in in vitro kinase activity.
2.3 Efﬁcient trans-autophosphorylation requires the SH2 domain
Autophosphorylation can occur intramolecularly (in cis) or intermolecularly (in trans). Initial
velocities of autophosphorylation of the Abl SH2-KD WT protein increased non-linearly
with enzyme concentration, showing possible intermolecular interactions (ﬁgure 2.8a-b).
The Van’t Hoff analysis (log of initial velocity vs log of protein concentrations) gave a linear
regression with a slope of 2 clearly conﬁrming a second-order reaction due to intermolecular
phosphorylation (ﬁgure 2.8b). This observation is in line with a trans-autophosphorylation
ability.
We speculated that one ore more tyrosine residues in the KD might be sterically less accessible
for phosphorylation, because the KD protein did not show a strong impairment of in vitro
kinase activity despite its inability to autophosphorylate. To test this hypothesis, we co-
incubated pairs of active (WT) and catalytically deﬁcients (D382N) KD and SH2-KD. Trans-
phosphorylation was then monitored in the D382N by the WT protein on Y412. Co-incubation
of active KD with inactive SH2-KD D382N showed robust trans-phosphorylation of the SH2-
KD D382N activation loop (ﬁgure 2.9a-b). On the contrary, the Abl SH2-KD WT despite being
a very active construct, was unable to trans-phosphorylate the Abl KD D382N in its activation
loop (ﬁgure 2.9).
Using a similar experiment set-up, we showed that the robust phosphorylation of SH2-KD
D382N by the KD was abolished by the disruption of the SH2-KD interface via the I164E
mutation (ﬁgure 2.9c-f).
These experiments showed that the SH2-KD interface seems to have a major impact on Y412
accessibility for being trans-phosphorylated because absence of the SH2 or disruption of the
interface renders the Y412 a poor substrate for phosphorylation (Lamontanara et al., 2014).
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Figure 2.6 – Disruption of the SH2-kinase interface impairs Abl autophosphorylation.
(a,d,g) Indicated Abl mutants were incubated for the indicated times with ATP, dot blotted
and incubated with total anti-pY (a), anti-pY412 (d) and anti-pY245 (g) antibodies. (b,e,h)
Normalized total pY, pY412 and pY245 were plotted over incubation time. (c,f,i) Relative
velocities of autophosphorylation for three biological repeats are shown. Average ±sd are
plotted. For each data set, the SH2-KD WT was set to 1 (NS, not signiﬁcant; **P<0.01,**P<0.001,
unpaired t-test). Figure modiﬁed from Lamontanara et al. (2014).
27
Chapter 2. Results
0 5 10 15 20 25
0.00
0.02
0.04
0.06
0.08
0.10
0.00
0.05
0.10
0.15
0.20
0.25
Time (min)
pY
24
5/
Ab
l (
A.
U
)
pY245
pY412
pY412/Total (A.U
)
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Y412 autophosphorylation. Ratio of phosphorylation intensities to Abl amount as detected by
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Figure 2.8 – Autophosphorylation of Abl SH2-KD WT at different protein concentrations.
(a) Recombinant kinases were incubated at different concentrations with 32P-γ-ATP, subjected
to SDS-PAGE and autoradiography. (b) Quantiﬁcation was done after gel drying using a
scintillation counter. The initial velocity vs kinase concentration (left) is shown as well as the
Van’t Hoff plot (right) clearly showing a second-order reaction and conﬁrming intermolecular
phosphorylation.
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Figure 2.9 – The activation loop is a poor substrate for trans-phosphorylation in the ab-
sence of the SH2-KD interface. (a,c) Models illustrating the two combinations tested in b,d
are shown. (b,d) Abl KD and SH2-KD were co-incubated for the indicated times and analyzed
by Western Blot using anti-pY412 antibody. (e) Normalized pY412 signals plotted over incu-
bation time for experiment shown in d. (f) Relative velocities for the autophosphorylation
reaction shown in d. The average of three independent experiments± s.d. are plotted. SH2-KD
WT was set to 1. Signiﬁcance levels compared to SH2-KD are indicated (***P<0.001, unpaired
t-test). Figure modiﬁed from Lamontanara et al. (2014).
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2.4 The Abl SH2 domain maintains an open conformation of the ac-
tivation loop
To assess the opening or closing of the Abl activation loop we used complexes with kinase-
inhibitors. Analysis of the Abl KD with imatinib showed a type 2 binding with a close activation
loop where the Y412 was not accessible for phosphorylation (Schindler et al., 2000). However
a crystal structure of Abl kinase-dasatinib complex showed a type 1 binding with an open
activation loop (Tokarski et al., 2006). Based on these observations, complexes of imatinib
or dasatinib with KD and SH2-KD were prepared and were conﬁrmed to be inactive and not
able to autophosphorylate (data not shown). We then used these kinase-drug complexes
as substrates for trans-autophosphorylation along with the SH2-KD and KD D382N and
monitored Y412 phosphorylation over-time.
Similar to KD-imatinib complexes, the KD D382N was defective in Y412 trans-phosphorylation
(ﬁgure 2.10a-c). This could be rescued (partially) in the KD-dasatinib complexe where the
Y412 phosphorylation readily increased in a linear manner. These results indicated that in the
Abl KD, the activation loop is in a closed conformation similar to the Abl-imatinib complex
and can be forced into opening when incubated with dasatinib.
We then included a 2xMyc-SBP tag to an active SH2–KD construct that allowed us to distinguish
two SH2-KD units once co-incubated using their different molecular weights. In contrast to
the results obtained with KD D382N, the SH2-KD D382N showed phosphorylation at Y412 to
a similar degree to the SH2-KD-dasatinib complex (ﬁgure 2.10d-f). Strikingly, the SH2-KD-
imatinib complex was strongly impaired in trans-phosphorylation at Y412 indicating that
imatinib induced the closed-activation loop conformation. These results showed that the
activation loop in the SH2–KD is similar to the dasatinib complex and is mostly populating
open conformations that are more readily accessible for trans-phosphorylation.
2.5 Targeting the Abl SH2-kinase interface with monobodies
To determine the sufﬁciency of targeting the Abl SH2-KD for Bcr-Abl inhibition, new mono-
bodies targeting the Abl SH2 have been developed. In collaboration with the Koide laboratory,
we characterized two new monobodies binding with a very high afﬁnity to the Abl SH2 and
inhibiting the formation of the SH2-KD interface.
2.5.1 Characterization of AS25 and AS27 monobodies
Two monobodies clones termed AS25 and AS27 harbouring a N-terminal 10xHis tag were
characterized by the Koide laboratory. They both bind the Abl SH2 in a very similar manner
with nM afﬁnity (10-20 nM, data obtained from Prof. Koide). The crystal structure of the
AS25-Abl SH2 complex has been obtained (data from S. Koide, ﬁgure 2.11a). AS25 forms a
cradled binding surface of more than 800 Å2 with the Abl SH2. Notably, the I164 is a central
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Figure 2.10 – The SH2 domain induces a fully active conformation of the activation loop.
(a,d) Active SH2-KD was co-incubated with dasatinib, catalytically inactive or imatinib-bound
KD (a) and SH2-KD (d) proteins for the indicated times and then analyzed by immunoblotting
with an anti-pY412 antibody. (b,e) Normalized pY412 signals of immunoblots in a,d were
plotted over time for the phosphorylated substrate (lower bands) of the reactions. (c,f) Relative
velocities of the trans-phosphorylation reactions from three independent experiments are
shown. Averages ±s.d. are plotted. For each data set, the dasatinib complex was set to 1.0.
Signiﬁcance levels in comparison with dasatinib-bound KD (c) or SH2-KD (f) are indicated
(NS, not signiﬁcant; ***P<0.001, unpaired t-test). Figure modiﬁed from Lamontanara et al.
(2014).
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residue that if mutated is expected to prevent the binding of AS25. AS25/27 binding is expected
to compete with and prevent the formation of the Abl SH2-KD interface.
AS25 and AS27 were puriﬁed with very high yields (>10 mg/L) using nickel afﬁnity beads
followed by a gel ﬁltration (ﬁgure 2.11b,c). The monobodies eluted in a main homogenous
peak (peak 2, ﬁgure 2.11c) at a calculated molecular weight of 10 kDa very close to the expected
one (12 kDa). Size-exclusion chromatography experiments showed efﬁcient formation of
AS25 complexes with Abl SH2-KD that was abolished with the I164E mutation conﬁrming the
central role of this residue for AS25/27 binding (data not shown).
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Figure 2.11 – AS25 binding mode and puriﬁcation. (a) Crystal structure of the AS25 mono-
body (orange, surface representation) binding to the Abl SH2 domain (green). The I164 is a
central residue (purple). (b) Coomassie staining of puriﬁed AS25 after NiNTA and gel ﬁltration.
Peak 1 and 2 are corresponding to the peaks in c. (c) The NiNTA elution was loaded on a
gel ﬁltration. AS25 eluted in a sharp peak (peak 2) at the expected molecular weight. Peak 1
corresponded to contaminants.
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Figure 2.12 – Inhibition of the Abl SH2-KD with monobodies in vitro. (a) The activity of Abl
KD (red) and SH2-KD (blue) were assayed against an optimal Abl peptide in the presence of
indicated concentrations of AS25 monobody. (b) Similar as in a but with the AS27 monobody.
2.5.2 AS25 and AS27 inhibit the Abl SH2-KD activity in vitro
Giving the very high overlap between the binding of the AS25/27 monobodies and the kinase
to the SH2 domain, we speculated that incubation of the monobodies with a puriﬁed Abl
SH2-KD might affect kinase activity. In vitro kinase assays were performed using Abl SH2-KD
or KD co-incubated with either the AS25 or AS27.
Substantial decrease of kinase activity of the SH2-KD was observed in a dose-dependent
manner when co-incubated with the monobodies (ﬁgure 2.12). Importantly, no inhibition
was detectable when KD was incubated with the monobodies arguing that the effect is SH2
dependent and speciﬁc. At the highest monobodies concentrations tested, the level of Abl
SH2-KD activity was similar to Abl KD (ﬁgure 2.12).
The data suggested that we could target the Abl SH2-KD in trans to reproduce the effects of the
I164E mutation. Therefore inhibition of Abl and Bcr-Abl by the monobodies was also tested in
a cellular context.
2.5.3 AS25 and AS27 expression decreased Abl PP and Bcr-Abl phosphorylation
in cells
To determine if AS25/27 could have an impact in a cellular context, HEK293 cells were co-
transfected with constitutively activated full-length Abl (Abl "PP") or Bcr-Abl together with
monobodies. We compared the effects of the two monobodies with a non-binding monobody
named HA4 Y87A, that is unable to bind the Abl SH2 (Wojcik et al., 2010).
Both AS25 and AS27 expression strongly decreased total phosphotyrosine level of HEK293
transfected with Abl PP by ≈50% (ﬁgure 2.13). Importantly, it almost abrogated Abl phospho-
rylation in the activation loop (Y412), a marker of activated Abl.
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Figure 2.13 – Inhibition of Abl phosphorylation in HEK293 cells by AS25 and AS27 mono-
bodies (a) HEK293 cells were co-transfected with a constitutively activated version of Abl
(Abl "PP") and different set of monobodies harbouring a Myc-tag. Besides AS25 and AS27,
HA4 Y87A was used as a negative non-binder control. Total tyrosine phosphorylation and
activation loop tyrosine 412 phosphorylation levels were normalized to total amount of Abl
PP expressed. Two repeats are shown for each monobody. (b) Relative total phosphotyrosine
levels of experiments shown in a. HA4 Y87A level was set at 1. (c) Relative pY412 levels of AS25
and AS27 experiments shown in a. HA4 Y87A level was set at 1. (d) AS25, AS27, the ﬁrst genera-
tion directed to the SH2-KD, 7c12, and HA4 Y87A were co-expressed as Myc-tagged proteins
with Abl PP and Abl PP I164E. Immunoprecipitation with an anti-Abl antibody revelead equal
levels of Abl PP in the immunoprecipitates (upper panel). Monobodies binding was detected
using anti-Myc antibody (lower panel). Signiﬁcance levels in comparison to HA4 Y87A are
shown (**P<0.01, *P<0.05, unpaired t-test).
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These results are in line with our previous observations that targeting the Abl SH2-KD interface
mostly has a negative inﬂuence on activation loop phosphorylation (ﬁgure 2.6). To conﬁrm
binding of the monobodies to the Abl SH2 domain in cells, Abl PP was immunoprecipitated
and the samples blotted with an anti-Myc antibody as the monobodies expressed were har-
bouring the tag (ﬁgure 2.13d). We used as a positive control the monobody 7c12 which was
already engineered to bind to Abl SH2-KD interface despite no strong physiological effects
(Grebien et al., 2011). As expected 7c12 was found bound to Abl PP while the HA4 Y87A engi-
neered to prevent monobody binding was not detectable after Abl pull-down. These results
conﬁrmed the speciﬁcity of the co-immunoprecipitation. AS25 and AS27 monobodies were
easily detected after Abl PP immunoprecipitation conﬁrming that they also bind Abl in cells.
Finally, the Abl PP I164E mutation prevented the binding of AS25/27 monobodies, conﬁrming
the importance of this residue for their binding to the SH2.
To further validate AS25 and AS27 monobodies, we also co-expressed them with the Bcr-Abl
kinase in HEK293 (ﬁgure 2.14). Expression of AS25/27 or 7c12 had no major effects on total
phosphotyrosine levels while expression of the I164E mutant decreased the level by more than
50 %. Interestingly, the levels of activation loop phosphorylation (pY412) were signiﬁcantly
decreased in cells expressing the monobodies AS25 (>50%, *P<0.05) and AS27 (>60%, *P<0.05),
altough not as strongly as in the case of the I164E mutation (>80 %, **P<0.01).
2.5.4 AS25 and AS27 induced cell death by apoptosis in K562 cells
Despite several attempts to constitutively express AS25/27 in the CML cell line K562, we were
unable to detect monobodies expression by western blot or ﬂow cytometry for a co-expressed
GFP six days after retroviral transduction. This difﬁculty prompted us to hypothesize that
AS25/27 expression could be incompatible with K562 cells proliferation or survival. To test this
possibility, we monitored the relative population of GFP positive, i.e. monobody-expressing
cells, starting 24h after retroviral infection of K562 cells. The cells expressing AS25 and AS27
were rapidly depleted in culture as shown by decreased GFP positivity over time (ﬁgure 2.15a).
This was not the case for cells expressing the non-binding mutant HA4 Y87A as well as the
HA4 monobody shown before to bind the Abl SH2 but which did not prevent the Abl SH2-KD
interface formation. In the case of AS25/27, the GFP positive population showed higher level
of early and late apoptosis as detected by Annexin V and 7-AAD staining (ﬁgure 2.15b-c). These
results indicated that AS25/27 induced apoptosis in K562 cells and that the observed effects
were not due to the transduction itself or simple monobody expression as the HA4 and HA4
Y87A monobodies had no effects (results obtained by B. Gerig).
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Figure 2.14 – Inhibition of Bcr-Abl phosphorylation in HEK293 cells by AS25 and AS27
monobodies. (a) HEK293 cells were co-transfected with Bcr-Abl expressing plasmid and
different set of monobodies harbouring a Myc-tag. Besides AS25 and AS27, HA4 Y87A was
used as a negative non-binder control. Total tyrosine phosphorylation and activation loop
tyrosine 412 phosphorylation levels were normalized to total amount of Bcr-Abl expressed. (b)
Relative total phosphotyrosine levels of experiments shown in a. HA4 Y87A level was set at 1.
(c) Relative pY412 levels of experiments shown in a. HA4 Y87A level was set at 1. Signiﬁcance
levels in comparison to HA4 Y87A are shown (**P<0.01, *P<0.05, unpaired t-test).
36
2.5. Targeting the Abl SH2-kinase interface with monobodies
Time after viral transduction 
(Day)
0 1 2 3 4 5 6
140
120
100
80
60
40
20
0
0 1 2 3 4 5 6
HA4 Y87A
HA4 
AS25
AS27
Time after viral transduction 
(Day)
R
el
at
iv
e 
po
pu
la
tio
n 
of
 G
FP
 
po
si
tiv
e 
ce
lls
 (%
 o
f d
ay
 1
)
K562
+ Retroviral vector for 
monobody & GFP
Mb+/
GFP+
Mb-
/GFP-
Flow cytometry
20
10
0
30
40
50
An
ne
xi
nV
 p
os
iti
ve
 (%
)
HA4 Y87A
HA4 
AS25
AS27
0
10
20
30
40
Time after viral transduction 
(Day)
0 1 2 3 4 5 6
7-
AA
D
 p
os
iti
ve
 (%
)
HA4 Y87A
HA4 
AS25
AS27
a
b c
Figure 2.15 – Effects of AS25 and AS27 monobodies on transduced K562 cells (a) K562 cells
were transduced with N-TAP fused monobodies (HA4, HA4 Y87A, AS25, AS27) and GFP positiv-
ity was followed overtime using ﬂow cytometry. (b) GFP positive cells were stained for Annexin
V and followed overtime. (c) GFP positive cells were stained for 7-AAD and followed overtime.
This experiment was carried out by B. Gerig.
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2.6 Development of screening assays for Abl SH2-KD interface dis-
rupters
Based on the previous results, we showed that the SH2-KD interface can be targeted and that it
inhibited Abl autophosphorylation and activity as well as affected K562 cells. As monobodies
are difﬁcult to deliver into cells, it was indispensible to develop a screening assay that could
lead to the ﬁnding of small-molecules mimicking the effects of the AS25/27 mononodies or
the I164E mutation.
2.6.1 Acrylodan-based ﬂuorescent assay
We thought to ﬁnd a way to detect interface disruption by harnessing Abl SH2 conformational
changes that could happen upon SH2-KD interface disruption. This would allow us to poten-
tially detect the disruption upon binding of small-molecules to either the Abl SH2 or tip of the
kinase domain. Recently, a ﬂuorescent molecule named acrylodan was sucessfully used to
detect compound binding to the myristate pocket in Abl (Schneider et al., 2012). Acrylodan is
a ﬂuorescent dye that can be coupled to cysteine residues via formation of a covalent thio-
ether bond at a neutral pH in aqueous solution. In solution, it has very low ﬂuorescent levels
but protein adducts of acrylodan become highly ﬂuorescent (ﬁgure 2.16a). The ﬂuorescent
properties of these adducts are particularly sensitive to conformational changes and ligand
binding (ﬁgure 2.16c).
We have selected three residues in the Abl SH2 domain at different sides and distances to the
SH2-kinase interface based on the crystal structure. The three positions have been mutated
to cysteines (L159C, T231C, E187C) while two exposed cysteines in the kinase domain have
been mutated to non-cysteine residues (C324V, C349S) (ﬁgure 2.16b). The goal was to prepare
recombinant Abl SH2-KD protein containing single engineered cysteine residues and being
either WT or carrying the I164E mutation as well as using the AS25 monobody to disrupt the
interface. Upon interface disruption, we were expecting a shift in acrylodan ﬂuorescence
compared to an intact SH2-KD interface (ﬁgure 2.16c). We would then select the positions
of the acrylodan label in the SH2 domain that show the strongest differences in the emission
spectrum between the WT (negative control) and the I164E or AS25-bound labelled SH2-KD
(positive controls).
All puriﬁed cysteine mutants showed good purity and stability (data not shown). Importantly
the C324V C349S double mutation in the kinase domain had no impact on Abl SH2-KD activity
as well as the SH2 cysteine mutants (ﬁgure 2.17). As expected, the mutants showed decreased
activity upon I164E mutation (ﬁgure 2.17). These results are in line with well-folded and stable
cysteine mutants that can be further used for labeling.
38
2.6. Development of screening assays for Abl SH2-KD interface disrupters
L159C
T231C
E187C
C324V
C349S
SH2
Kinase
N
O
+RSH
a b
N
O
SR
Low fluorescence
High fluorescence
Positive control 
(I164E, AS25)
Hit Compound not disrupting 
the interface
Negative control
c
Figure 2.16 – Acrylodan-based screening principle. (a) Acrylodan has a low ﬂuorescence that
is increased upon thioether bond formation with a cysteine (RSH) (b) Positions of engineered
cysteine mutations in the SH2 and the cysteine residues that were removed from the kinase
domain. (c) Schematic representation of the proposed screening assay. Abl SH2 domain is
depicted in green and kinase domain in blue. Once bound to the cysteine mutant in the
SH2 domain, acrylodan will have high ﬂuorescence (red). Any SH2-KD dirsuption via I164E
mutation, monobodies or a hit compound will shift the ﬂuorescence (yellow). Binding of a
compound to a surface not disrupting the interface will not affect ﬂuorescence.
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Figure 2.17 – Kinase activity of Abl SH2-KD cysteine mutants. Puriﬁed Abl cysteine mutants
were assayed for kinase activity against an optimal Abl peptide and the kinetics ﬁtted using
the Michaelis-Menten equation. The maximum velocity is shown for each mutant.
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Labeling of acrylodan SH2-KD mutants
To conﬁrm correct labeling of the different cysteine mutants, we compared the labeling of
the mutants with the Abl SH2-KD C324V C349S (SH2-KD*) that has no cysteines in the SH2
domain and for which two exposed cysteines have been mutated in the kinase domain to
avoid kinase labeling. Acrylodan ﬂuorescence has a main emission peak between 500-520 nm
after excitation at 380 nm. Acrylodan alone in solution showed low ﬂuorescence as expected
(ﬁgure 2.18a). When any of the protein mutants was incubated with acrylodan in solution, a
drastic increase in ﬂuorescence was observed over the whole emission spetrum (ﬁgure 2.18b).
This conﬁrmed that acrylodan had reacted with cysteines in the proteins and thus became
ﬂuorescent. Out of the three cysteine mutants, Abl SH2-KD* E187C and L159C showed high
ﬂuorescence at their maximum (≈ 500 nm) compared to the control SH2-KD*. The last mutant,
T231C, did not have an increase in ﬂuorescence at the maximum of emission compare to Abl
SH2-KD* (ﬁgure 2.18b).
Altough not having any exposed cysteines, the Abl SH2-KD* also showed increased ﬂuores-
cence. This increase could be due to a non-speciﬁc labeling of the Abl SH2-KD* kinase domain.
Indeed mass spectrometry analysis of labeled Abl SH2-KD* showed that a minor proportion of
the population was labeled with acrylodan (data not shown), which was enough to increase
ﬂuorescence of acrylodan in solution.
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Figure 2.18 – Fluorescence spectrum of Abl SH2-KD cysteine mutants. (a) Fluorescence
spectrum of acrylodan only in solution. (b) Abl SH2-KD cysteine mutants were labeled
with acrylodan overnight and assayed for ﬂuorescence by exciting acrylodan at 360 nm and
detecting excitation between 400-550 nm. 10 μM of proteins were used.
Analysis of acrylodan cysteine mutants upon interface disruption
To further continue analyzing the Abl SH2-KD cysteinemutants, we compared the ﬂuorescence
spectrum of the labeled mutants with or without the I164E mutation. Among the three
mutants, only labeled Abl SH2-KD* E187C showed a decreased emission ﬂuorescence at 500
nm upon interface disruption via I164E mutation, while no major shift of the maximum
wavelength of emission was observed (ﬁgure 2.19b).
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To mimick interface disruption in trans by possible small-molecules, we used the monobody
AS25 as a positive control, which efﬁciently affected kinase activity in our biochemical as-
says. We co-incubated the SH2-KD* E187C mutant with several concentrations of the AS25
monobody. Increasing concentrations of AS25 monobody induced a decreasing maximum ﬂu-
orescence of the labeled Abl SH2-KD* E187C from 35000 to less than 25000 A.U at monobody
concentration of 25-40 μM (ﬁgure 2.20a) and showing a sigmoidal response (ﬁgure 2.20c).
No major shift of the peak maxima was observed. As a control, we used an unrelated mono-
body (Nsa5, Sha et al. (2013)) of a similar molecular weight than AS25. Incubation of Nsa5
concentration ranging from 17 to 40 μM had no impact on maximum ﬂuorescence (ﬁgure
2.20b). These results were in line with a speciﬁc decrease of maximum ﬂuorescence upon Abl
SH2-KD interface disruption. Despite robust ﬂuorescence, the calculated Z’ factor with the
acrylodan-labeled Abl SH2-KD* E187C and using AS25 as a positive control only reached 0.4,
which is considered as marginal (<0.5).
450 500 550
0
10000
20000
30000
40000
Wavelength (nm)
SH2-KD* T231C
SH2-KD* T231C I164E
450 500 550
0
20000
40000
60000
Wavelength (nm)
SH2-KD* E187C 
SH2-KD* E187C I164E
450 500 550
0
20000
40000
60000
80000
Wavelength (nm)
SH2-KD* L159C 
SH2-KD* L159C I164E
a b
c
Fl
uo
re
sc
en
ce
 (A
.U
.)
Fl
uo
re
sc
en
ce
 (A
.U
.)
Fl
uo
re
sc
en
ce
 (A
.U
.)
Figure 2.19 – Fluorescence spectrum of Abl SH2-KD cysteine mutants comparing intact
SH2-KD interface and disrupted interface via I164E mutation. Each cysteine mutant, either
WT or harbouring the I164E mutation was labeled with acrylodan and ﬂuorescence spectrums
compared. (a) Spectrum comparison of Abl SH2-KD* T231C and Abl SH2-KD* T231C I164E.
(b) Spectrum comparison of Abl SH2-KD* E187C and Abl SH2-KD* E187C I164E. (c) Spectrum
comparison of Abl SH2-KD* L159C and Abl SH2-KD* L159C I164E.
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Figure 2.20 – Effect of AS25 on ﬂuorescence spectrum of Abl SH2-KD* E187C. (a) Acrylodan-
labeled SH2-KD* E187C was incubated with increasing concentrations of AS25 monobody
and ﬂuorescent spectrum measured. (b) Acrylodan-labeled SH2-KD* E187C was incubated
with increasing concentrations of Nsa5 monobody and ﬂuorescent spectrum measured. (c)
Maximum ﬂuorescence obtained from a was plotted over logarithmic concentrations of AS25.
2.6.2 HTRF-based screening assay
In order to develop a more robust assay we thought to develop a screening assay based on the
binding of AS25 to the Abl SH2. This interaction is well-characterized, strong (nM afﬁnity) and
binding of AS25 indeed disrupted the SH2-KD interface as previously shown by the decreased
Abl activation loop phosphorylation (see Section 2.5.3). A compound that could bind and
disrupt the SH2-AS25 interaction would mimick the effect of AS25 and might disrupt the Abl
SH2-KD interaction.
With the help of Cisbio (France) and their expertise in Homogenous Time-Resolved Fluores-
cence (HTRF), a screening assay development was started. HTRF couples the advantages of
ﬂuorescence resonance energy transfer (FRET) with time-resolved (TR) measurements. FRET
is based on the transfer of energy between a donor (long-lived ﬂuorescence) and acceptor
(short-lived ﬂuorescence) when the two are in close proximity. HTRF has the advantage to use
long-lived acceptor ﬂuorophores when engaged in a FRET process, increasing reliability and
assay sensitivity. By introducing a time-delay (50-150 μs) between the initial light excitation
and ﬂuorescence measurements, HTRF allows the elimination of short-lived background ﬂuo-
rescence such as compounds, medium or protein ﬂuorescence. The assay will use tag-labeled
AS25 and SH2 in which the tags are detected using anti-tag molecules labeled with donor
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and acceptor ﬂuorophores (ﬁgure 2.21a). Any compound binding to the AS25-SH2 interface
and disrupting it will induce a decrease in the overall HTRF signal because of the donor and
acceptor being far apart when the complex is not formed (ﬁgure 2.21b).
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Figure 2.21 – Screening principle using indirect HTRF. The Abl SH2 is labeled with a chosen
tag (tag 1) and AS25 with a second tag (tag 2). Tag 1 is detected with an anti-Tag 1 harbouring a
donor ﬂuorescent molecule (D), while the anti-Tag 2 harbours the acceptor molecule (A). (a)
When both SH2 and AS25 are interacting the donor is in close promixity with the acceptor and
an HTRF signal is generated through ﬂuorescence resonance energy transfer once the donor
is excited. (b) When the interaction is disrupted by a compound X binding to the Abl SH2, no
HTRF is detected as the donor and acceptor are far apart in solution. (c) Coomassie staining
of puriﬁed AS25 and SH2 versions used for the HTRF screening.
During the process development, we have decided to use AS25 and Abl SH2 with different tags
and positions (either N-or C-terminal) to maximize the chance of ﬁnding the best possible
pair and obtain a good signal/noise ratio. We have puriﬁed AS25 harbouring either N-terminal
10xHis-Flag tag or C-terminal 6xHis-Tag. The Abl SH2 was puriﬁed with a N-terminal GST
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tag or harbouring a biotinylation at the N-or C-terminus (ﬁgure 2.21c). We chose to use as a
donor Terbium (Tb)-Cryptate which is one of the brightest available at Cisbio. As acceptors,
two molecules were used, either XL665 or d2. In total 28 combinations were tested by Cisbio
(table 2.3).
Table 2.3 – Tested HTRF pair combinations. 28 HTRF pairs were tested using different anti-
bodies (anti-), or Streptavidin (Strept) bound to one donor: Terbium (Tb) and two acceptors :
d2 and XL665.
Combination AS25 SH2
Tag Anti-tag Tag Anti-tag
1 N-His Tb-Anti-His N-Biot d2-Strept
2 N-His Tb-Anti-His N-Biot XL665-Strept
3 N-His Tb-Anti-His C-Biot d2-Strept
4 N-His Tb-Anti-His C-Biot XL665-Strept
5 N-His d2-Anti-His N-Biot Tb-Strept
6 N-His d2-Anti-His C-Biot Tb-Strept
7 N-His XL665-Anti-His N-Biot Tb-Strept
8 N-His XL665-Anti-His C-Biot Tb-Strept
9 N-Flag Tb-Anti-Flag N-Biot d2-Strept
10 N-Flag Tb-Anti-Flag N-Biot XL665-Strept
11 N-Flag Tb-Anti-Flag C-Biot d2-Strept
12 N-Flag Tb-Anti-Flag C-Biot XL665-Strept
13 N-Flag Tb-Anti-Flag N-GST d2-Anti-GST
14 N-Flag Tb-Anti-Flag N-GST XL665-Anti-GST
15 N-Flag d2-Anti-Flag N-Biot Tb-Strept
16 N-Flag d2-Anti-Flag C-Biot Tb-Strept
17 N-Flag d2-Anti-Flag N-GST Tb-Anti-GST
18 N-Flag XL665-Anti-Flag N-Biot Tb-Strept
19 N-Flag XL665-Anti-Flag C-Biot Tb-Strept
20 N-Flag XL665-Anti-Flag N-GST Tb-Anti-GST
21 C-His Tb-Anti-His N-Biot d2-Strept
22 C-His Tb-Anti-His N-Biot XL665-Strept
23 C-His Tb-Anti-His C-Biot d2-Strept
24 C-His Tb-Anti-His C-Biot XL665-Strept
25 C-His d2-Anti-His N-Biot Tb-Strept
26 C-His d2-Anti-His C-Biot Tb-Strept
27 C-His XL665-Anti-His N-Biot Tb-Strept
28 C-His XL665-Anti-His C-Biot Tb-Strept
The ﬁrst trial with all combinations was done in a 4 by 4 matrix testing 4 concentrations
of each protein (0, 3, 30 and 300 nM). Sufﬁcient signal-to-noise ratio was mostly obtained
with both proteins co-incubated at 300 nM (data not shown). Among the 28 combinations, 8
combinations showed comfortable signals (ﬁgure 2.22, signal-to-noise ratio over 3).
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Figure 2.22 – Signal-to-noise ratio of 28 HTRF pair combinations. 28 HTRF pair combina-
tions described in table 2.3 were tested with 300 nM of both AS25 and Abl SH2. Signal-to-noise
ratios above 3 were considered as reliable (horizontal dash line). Data obtained by Cisbio
France.
Most efﬁcient combinations were observed with N-term 6xHis AS25 when detected by an
anti-His bound to the Terbium donor and biotinylated SH2 detected by streptavidin bound
to both d2 and XL665 (combination 1 to 4,7 and 8), with slightly better signals obtained with
C-term biotinylation (combinations 3 and 4). The combination 3 with Streptavidin-d2 gave
a signal almost two times higher than with XL665. Combinations detecting N-term 6xHis
AS25 with an anti-His bound to the acceptor instead of donor were efﬁcient only if the donor
was XL665 (combination 7 and 8) and again C-term biotinylated SH2 version was better
(combination 7). Signal-to-noise above 3 were obtained with C-term 6xHis AS25 only when
the anti-His antibody was bound to the XL665 acceptor but not d2 (combination 27 and 28)
nor the Terbium donor (21 to 24), with this time N-term biotinylated SH2 showing improved
signals (combination 27). All combinations using anti-Flag antibodies detecting the N-term
Flag AS25 or anti-GST against GST-SH2 failed to give sufﬁcient signals (9 to 20).
To further continue the analysis, the combinations 3, 8 and 27 were selected in order to have
enough variation in the type of combination while keeping a good signal. Each combination
was repeated two times with combination of 30 and 300 nM concentrations (ﬁgure 2.23).
For the three combinations, as expected, the signal was high enough only when both AS25
and SH2 were co-incubated at 300 nM. Interestingly, the repeats 2 and 3 had very similar
signal-to-noise ratio but were lower than the ﬁrst trial, while still above 3, for all the three
combinations (ﬁgure 2.23). Of note, samples were frozen and thawed between trials 1 and 2/3.
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Figure 2.23 – Repeats of combinations 3, 8 and 27 at different protein concentrations. Com-
binations 3, 8 and 27 were repeated three times at several protein concentrations to conﬁrm
sufﬁcient signal-to-noise ratio. Data obtained by Cisbio France.
Most of the combinations showed good signal overtime even after 18 hours incubation (ﬁgure
2.24). Combinations 8 and 27 showed excellent stability with the signal-to-noise ratio decreas-
ing less than 10% after 18 hours. Combination 3 showed a decreasing signal overtime (≈ 50%
after 18 hours).
The next important step was to show that the signal observed was speciﬁc. For that purpose,
tagged AS25 and SH2 were incubated together with a cleaved, untagged, AS25. Overnight
incubation with a 100-fold excess of cleaved AS25 returned the HTRF signal to the control
(background) level for all 3,8 and 27 combinations, conﬁrming that the observed signal was
due to the AS25-SH2 interaction and can be competed with an excess of untagged AS25 (ﬁgure
2.25).
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Figure 2.24 – Time-course signal-to-noise ratio of combinations 3,8 and 27. Signal-to-noise
ratio of combinations 3,8 and 27 were measured at 5 different times points (hours) to assess
for signal stability. Data obtained by Cisbio France.
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Figure 2.25 – Effect of cleaved AS25 on HTRF signal. Effect of competition by untagged AS25
was tested on combinations 3,8 and 27. HTRF signals of control experiments (no ﬂuorophores)
or AS25-SH2 complex at 300 nM were measured without (blue) and with (red) overnight
co-incubation of untagged AS25. Data obtained by Cisbio France.
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2.7 Roles of non-catalytic domains in cytoplasmic tyrosine kinases:
focus on the Btk kinase
2.7.1 Targeted cytoplasmic tyrosine kinases and expression levels
We have selected 10 kinases (Btk, Csk, Hck, Lck, Src, Zap70, Syk, Ack, Fes and Brk) spanning 7
CTK families (Src, Csk, Brk, Tec, Fes, Syk, Ack) and tried to express several constructs in BL21
E. coli cells using the YopH co-expression strategy as well as transfected HEK293 cells. While
most of the constructs showed detectable expression (Western Blot) in HEK293, recombinant
expression in BL21 cells was more heterogenous. Some kinase domains were not expressed or
mostly insoluble (Syk/Zap70, Lck/Hck) while others showed low-medium (Brk, Btk) to high
yields (Csk, Fes, chicken-Src).
Table 2.4 – Selected cytoplasmic tyrosinekinases andexpression inBL21andHEK293 cells.
Kinase Construct Yield in E. coli (BL21) Expressed in HEK293
Btk KD 1 mg/L Yes
SH2-KD <0.5 mg/L Yes
SH3-SH2-KD <0.5 mg/L Yes
Full-length 1 mg/L Yes
Csk KD 2 mg/L Yes
SH2-KD 5 mg/L Yes
Full-length >5 mg/L Yes
Lck/Hck KD Not expressed Yes
SH2-KD N.D Yes
Full-length N.D Yes
Src(chicken) KD >5 mg/L N.D
SH3-SH2-KD >5 mg/L N.D
Brk KD <1 mg/L Yes
SH2-KD <1 mg/L Yes
Full-length N.D Yes
Zap70/Syk KD Insoluble Yes
SH2-KD N.D Yes
Full-length N.D Yes
Fes SH2-KD >5 mg/mL N.D
Ack KD Not expressed Yes
KD-SH3 N.D Yes
SAM-KD-SH3 N.D Yes
SAM-KD N.D Yes
Full-length N.D No
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Figure 2.26 – Puriﬁcation of Zap70 KD from transfected S2 cells. (a) Zap70 KD and Abl SH2-
KD D382N (control) were expressed and puriﬁed from S2 cells after transfection. (b) Puriﬁed
Zap70 KD in (a) was for tested kinase activity against an optimal Abl peptide (Abltide). Co-
incubation of Zap70 KD with Abltide increased the raw count per minute by more than 4 times
(CPM) (n = 2).
2.7.2 Expression trials in S2 insect cells
In order to be able to express fast and reliable amount of several CTKs constructs that were
difﬁcult targets in E. coli, we thought to develop in collaboration with David Hacker (EPFL) a
transfection system using S2 drosophila cells. Trial assays with Zap70 KD, which was not ex-
pressed in BL21 cells, was compared to the expression of the Abl SH2-KD D382N (catalytically
inactive) expected to be easily expressed, both containing a C-terminus 6xHis tag.
3 days after S2 cells transfection (300mL), we have carried out cell lysis and protein puriﬁcation.
After a one step-puriﬁcation using NiNTA beads, a band at the expected molecular weight was
observed for both Zap70 KD and Abl SH2-KD D382N, as well as a relatively good purity (ﬁgure
2.26a). Estimated yields were 2 mg/L for Zap70 and more than 4 mg/L for Abl SH2-KD D382N.
Importantly, the puriﬁed Zap70 KD showed activity against Abltide in an in vitro assay (ﬁgure
2.26b).
2.7.3 Role of non-catalytic domains in activation loop phosphorylation
We have selected kinases for which activation loop phosphorylation antibodies were available.
Among the chosen kinases, we obtained antibodies detecting activation loop phosphorylation
for Btk, Brk, Lck/Hck, and Zap70. No signal was obtained despite several trials for the Zap70
kinase (data not shown). After transfection in HEK293 cells, Btk and Brk showed a strong
dependence on non-catalytic domains for activation loop phosphorylation whereas it was not
the case for Hck (ﬁgure 2.27).
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Figure 2.27 – Activation loop phosphorylation of several Btk, Brk and Hck kinases con-
structs in HEK293 cells. Several constructs were transfected in HEK293 for Btk (a), Brk (b)
and Hck (c) kinases. Samples were blotted for anti-Myc (total protein expressed) and speciﬁc
anti-phospho antibodies detecting activation loop phosphorylation for each kinase. Quantiﬁ-
cation of activation loop phosphorylation is shown relative to the level of the KD constructs
for Btk (d), Brk (e) and Hck (f). FL: Full-length, KD: Kinase domain.
Almost no phospho-Y551 was detectable for Btk KD but adding the SH2 domain increased
level drastically (>500-fold), and presence of both SH3 and SH2 gave an even stronger signal
(>2500-fold increase), while the full-length construct showed a lower activation level (>250-
fold). Brk kinase showed also a signiﬁcant increase upon addition of the SH2 domain compare
to the KD only (>4 fold), and a similar increase was also observed with the full-length protein.
Given the strong effects of both SH2 and SH3 domain on Btk kinase activation loop phos-
phorylation, we have further studied the activation loop phosphorylation of Btk kinase using
mutants proteins. A preliminary study of several mutants that should affect SH2 (R307G,
S309N) or SH3 (W251L) canonical binding as well as a kinase dead (D521N) and activation
loop deﬁcient mutant (Y551F) was carried out (ﬁgure 2.28). To conﬁrm that the R307G and
S309N mutants were indeed deﬁcient in phosphotyrosine binding, we have used a ﬂuorescent
polarization assay that conﬁrmed the R307G mutant as deﬁcient in phosphotyrosine binding
but not the S309N mutant which was only slighly affected (ﬁgure 2.28c-d). The R307G muta-
tion did not affect the Abl SH2 folding in vitro. The SH3 W251L mutant was previously shown
to prevent poly-proline motif binding and used in several studies (Yang et al. (1995), Yang and
Desiderio (1997)). Interestingly, preventing phospho-tyrosine binding on the Btk SH2-KD con-
struct did not affect pY551 level. On the contrary the Btk SH3-SH2-KD high phosphorylation
level was drastically reduced upon disruption of phosphotyrosine binding, while preventing
canonical binding of its SH3 only slighty decreased activation loop phosphorylation.
50
2.7. Roles of non-catalytic domains in cytoplasmic tyrosine kinases: focus on the Btk
kinase
Finally, the kinase dead mutation completely prevented phosphorylation level of the SH3-
SH2-KD construct, arguing for an autophosphorylation mechanism (ﬁgure 2.28a-b). No signal
was observed upon mutation of the Y551 to phenylanine (Y551F). Overall the results showed
strong autophosphorylation ability of the Btk kinase in HEK293 cells, dependent on both the
SH2 and SH3 domains, while the KD only was unable to undergo autophosphorylation in
cells.
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Figure 2.28 – Effect of several Btk mutants on activation loop phosphorylation. (a) Several
mutant constructs of Btk SH2-KD and SH3-SH2-KD were transfected in HEK293 cells. (b)
pY551 levels relative to WT construct were quantiﬁed. (c) Fluorescence polarization analysis
of the Btk SH2 R307G and S309N mutants. (d) Far-UV spectrum of Btk SH2 WT and R307G.
2.7.4 Btk kinase autophosphorylation in vitro
Btk kinase autophosphorylation on its activation loop was analyzed in vitro using puriﬁed
recombinant Btk kinase from E. coli as described in Wang et al. (2015). Puriﬁed Btk KD au-
tophosphorylated very slowlywhile the presence of the Btk SH2 domain dramatically increased
autophosphorylation rate (ﬁgure 2.29a-b). Despite a strong impairment of Btk KD autophos-
phorylation ability, no signiﬁcant differences were observed in kinase activity between Btk KD
and SH2-KD (ﬁgure 2.29c). This conﬁrmed that both Btk KD and SH2-KD puriﬁed proteins
were behaving well in solution and that the slow rate of Btk KD autophosphosphorylation was
not due to unfolding of the protein or stability issues. The Btk SH3-SH2-KD construct was
impaired in activation loop autophosphorylation with an autophosphorylation rate very close
to the one of Btk KD.
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Figure 2.29 – Autophosphorylation ability of Btk kinase in solution. (a) Several Btk con-
structs (KD, SH2-KD and SH3-SH2-KD) were incubated with ATP and reaction stopped at
different time points. Samples were immunoblotted with anti-Btk and anti-pY551 antibodies.
(b) Activation loop phosphorylation levels were quantiﬁed using the Li-Cor system.(c) In
vitro kinase activity of Btk SH2-KD and KD against Abltide. The kinetics were ﬁtted using the
Michaelis-Menten equation (n = 3).
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3.1 Role of the Abl SH2 domain in the kinase autophosphorylation
Despite expected differences in kinase activity when the Abl SH2-KD interface was disrupted
via the I164E mutation (1.5 fold decrease) or increased via the T231R mutation (1.2 fold
increase), the observed effects were mild and might not explain such a profound effect of
interface disruption on transformation and leukemogenesis (Grebien et al., 2011). These
effects are in line with a recent study using similar constructs (Lorenz et al., 2015). Regardless
of robust kinase activity, the Abl KD was strongly deﬁcient in autophosphorylation ability.
Importantly, the I164E mutation did not affect the phospho-tyrosine binding of the SH2
(Grebien et al., 2011)
Most of the in vitro autophosphorylation sites strongly overlapped with cellular phosphoryla-
tion sites. This result does not exclude the possibility that Abl or Bcr-Abl can be phosphorylated
by other tyrosine kinases in cells; however, this ﬁnding suggests that autophosphorylation
likely plays a pivotal role in the Abl-activation process. Especially it has been shown that
phosphorylation of Y412 in the activation loop was required for transformation of ﬁbroblasts
and hematopoietic progenitors (Pendergast et al., 1993).
We used type 1 and 2 Abl inhibitors to monitor activation loop conformation in the absence
and presence of the SH2 domain using Y412 trans-phosphorylation assays. Dasatinib (type
1) converted the Abl KD from an inert to a good substrate for Y412 phosphorylation. This
conﬁrmed previous results obtained using NMR spectroscopy where dasatinib was shown
to induce strong conformational shifts of Abl activation loop in solution (Vajpai et al., 2008).
Interestingly, increased activation loop phosphorylation was also observed with JAK kinases
type 1 inhibitors in a cellular set up (Andraos et al., 2012). This suggests that inhibitor-bound
kinases gain some functional and conformational properties despite blockade of ATP binding
and caution is needed when using the activation loop as a marker of kinases activation. On
the contrary, Abl SH2-KD Y412 trans-phosphorylation was decreased when in complex with
imatinib, conﬁrming the closing of the activation loop by this type 2 inhibitor.
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These trans-phosphorylation assays using inhibitor-bound Abl SH2-KD and KD constructs
showed that the SH2 is an allosteric activator of activation loop opening, inducing Y412
phosphorylation. Based on the results we built a model where the activation loop is in an
equilibrium between an open (active) and closed (inactive) conformation and for which the
equilibrium is switched to the open conformation once the Abl SH2-KD interface is formed
(ﬁgure 3.1). Disruption of the interface would favor the closed conformation as in the case of
the KD only. The activation loop opening via SH2 binding to the kinase was also observed in
molecular dynamics using in silico modelling in recent studies (Dölker et al. (2014), Tse and
Verkhivker (2015)).
An abundant phosphorylation site in the SH2-KD linker was also detected: Y245 as previously
observed (Brasher and Van Etten, 2000). The high levels of Y245 phosphorylation observed in
our constructs suggests a strong phosphorylation consensus and excellent accessibility. While
the structural role of Y245 in the inactive conformation is well understood, the consequences
of its phosphorylation in the active conformation is unclear. Our autophosphorylation assays
showed that phosphorylation of Y245 is also required for full activation loop phosphorylation,
suggesting a temporal and functional coupling of Y412 and Y245. In addition, targeting the
Abl SH2-KD interface had no impact on Y245 phosphorylation. Phosphotyrosine-binding
by the SH2 was also required for efﬁcient phosphorylation of Y412, but not of Y245. While
a transient intermolecular interaction of SH2 binding to phospho-Y245 could be envisaged;
however, no apparent dimerization of Abl SH2-KD upon autophosphorylation was observed.
This type of mechanism is difﬁcult to prove without a higher resolution crystal structure of
phosphorylated Abl SH2-KD. Further functional studies have to be done to provide a reliable
mechanistic explanation of these results.
Overall, we presented evidence that mechanisms of Abl activation can be deciphered using
recombinant kinase produced in E. coli. This approach enabled us the understanding of
a mechanism linking Abl SH2 allosteric regulation to two-phosphorylation events with an
emphasis on activation loop phosphorylation.
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Figure 3.1 – Role of the Abl SH2-KD interface in activation loop opening summarized in a
graphical model. (a) The Abl KD has a predominantly inactive activation loop conformation
that is similar to the conformation once imatinib or other type-2 kinase inhibitor are bound.
(b) Once the SH2-KD interface is formed, the equilibrium is shifted to a predominantly open
activation loop similar to the conformation once dasatinib or type-1 inhibitors bind to the KD.
TKI: tyrosine kinase inhibitor. Figure modiﬁed from Lamontanara et al. (2014).
3.2 Disruption of the Abl SH2-KD interface using monobodies
In order to establish the feasibility of targeting the Abl SH2-KD, we used two new monobodies
termed AS25 and AS27 binding the SH2 domain that should compete with the KD binding. We
ﬁrst analyzed the effects of AS25 and AS27 on kinase activity using recombinant Abl SH2-KD
and KD. The results were in line with the monobodies competing with kinase binding and
disrupting the SH2-KD interface. Observed effects were obtained only at μM concentration
ranges of monobodies. This was suprising as their binding afﬁnities are in the nM concentra-
tion range. Possible unstability/precipitation of puriﬁed AS25 and AS27 was excluded as they
eluted at the expected molecular weight during gel ﬁltration and monobodies are very stable
molecules. It is possible that the binding between Abl SH2-KD and Abl SH2 differs because of
the presence of the KD.
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Although there is often a good correlation between binding afﬁnity of competitive inhibitor
and their IC50 values in enzyme inhibition assays, for allosteric inhibition this is often not the
case. Most notably, the allosteric Bcr-Abl inhibitor GNF-2/5 and its successor ABL001, that
target the Bcr-Abl myristoyl binding site, showed no or only moderate inhibition in in vitro
kinase assays, despite their low nanomolar binding afﬁnities (Adrián et al., 2006). In general,
and especially for allosteric inhibitors, afﬁnity does not always directly translate to efﬁcacy
and biological effects.
AS25
7c12
SH2
I164
Figure 3.2 – Comparison of AS25 and 7c12 binding to Abl SH2. 7c12 (blue cartoon) binds
to a different epitope when compared to AS25 (orange ribbon), further away from the I164
residue.
Both AS25 and AS27 binding to Abl PP or Bcr-Abl in cells were decreasing activation loop
phosphorylation, in line with the effects observed in vitro when disrupting the SH2-KD
interface via the I164E mutation (ﬁgure 2.14). The binding mode of 7c12 to the Abl SH2 is
different from AS25 although partially overlapping (ﬁgure 3.2). Indeed, AS25 is binding in a
very similar location as does the Abl KD, cradling the SH2 domain with I164 being a central
residue. On the contrary, 7c12 is binding closer to the SH2 side, not being directly in contact
with the I164E residue and further away from the KD binding site. It is not surprising therefore
to observe stronger effects on Abl autophosphorylation and cell survival with Abl AS25/27.
This is also a clear indication that potential therapeutics should bind closely to the I164 residue
and that a potential molecule binding to the site as does 7c12 will likely have no effects.
We have also shown that AS25 and AS27 expressing K562 cells showed increased apoptosis
overtime. This was a sign that monobody binding to Bcr-Abl SH2-KD interface affected cells
dependent on the kinase. This experiment must now be completed by testing the monobodies
in cells independent on Bcr-Abl. Indeed, speciﬁcity of AS25/AS27 in cells has to be evaluated
and the monobodies should not affect cells that do not express Bcr-Abl, such as Ba/F3 cells.
Because K562 cells were affected by the expression of AS25/27, it was impossible to do pull-
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down analysis to check for AS25/27 speciﬁcity in cells via mass spectrometry, as usually done
for monobodies. Cell lines independent on Bcr-Abl should be used to check for possible off-
target binding and conﬁrm that the observed effects are speciﬁc for the Abl SH2-KD interface.
Future experiments should also analyzed the effects of monobodies on phosphorylation of
downstream Abl substrates such as STAT5, a clear indicator of Bcr-Abl activity in K562.
3.3 Screening assay development for Abl SH2-kinase interface dis-
rupters
We ﬁrst thought to develop a screening assay using a ﬂuorophore which is able to detect
changes in protein conformation (acrylodan). Based on a recent study (Schneider et al., 2012)
where acrylodan was used to detect Abl myristate binders, we labeled several Abl SH2-KD
cysteine mutants with acrylodan. Despite a clear ﬂuorescence increase conﬁrming labeling of
the mutants, most showed no or little (E187C) change in ﬂuorescence spectrum upon interface
disruption with AS25. In general, once incubated with acrylodan, protein precipitation could
be observed resulting in non-negligible protein loss. Even if binding of AS25 seemed to alter
the maximum ﬂuorescence of one of the mutant (E187C), only a decrease in ﬂuorescence was
observed, while acrylodan-based assays usually show also altered ﬂuorescence spectrum with
apparition or loss of secondary peaks in ﬂuorescence. This was important as that type of assay
is sensitive to the intrinsic ﬂuorescence of tested compounds which can quench or increase
the signal, leading to increasing false-positive or negative (Schneider et al., 2013). We doubted
the robustness of this assay using the mutant we have chosen, and the calculated Z’(0.4)
conﬁrmed that the assay was marginal. Giving the tedious labeling of the Abl SH2-kinase and
lack of robustness of the assay, we tried to ﬁnd a way of using unlabeled protein that could be
easily produced and at high yields.
Because the AS25 binding to Abl SH2 was well-characterized and we could show that it had
biological effects, we postulated that some compounds binding to Abl SH2 and preventing
the Abl SH2-AS25 complex formation might also later impair the Abl SH2-KD formation. In
collaboration with Cisbio, we have developed an HTRF-based screening assay that will be able
to detect small-molecules disrupting the formation of the Abl SH2-AS25 complex. The results
showed high signal-to-noise ratios with several combinations and a complete abrogation
of the signal when using an untagged AS25 as a competitor. A second optimization phase
is currently ongoing with the combination 8 selected as the most reliable and stable pair.
Further optimization will include testing other types of buffers, several concentrations of both
proteins as well as reagents (antibodies or strepatividin bound to donor/acceptor) and the
effects of freeze/thaw cycles. The screening method has been validated by the Biomolecular
Screening facility (BSF) and the ﬁrst screening trials are expected to be done early in 2016
(April-May). The BSF gives access to a library of more than 65.000 compounds and we are
planning to start the screening using a dedicated protein-protein interaction inhibitors library
(5441 compounds, Life Chemicals).
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Only very few screening assays to ﬁnd alloteric inhibitors are being currently developed or
used. The real bottleneck is the lack of screening methods for such type of inhibitors as well
as a limited knowledge of allosteric regulation among most of the targeted kinome. We hope
that the use of monobodies could help in developing such assays in order to discover small-
molecules binding to allosteric sites and important protein-protein interactions in cancer
pathways.
3.4 Allosteric regulation in cytoplasmic tyrosine kinases
3.4.1 Recombinant protein expression strategy
In order to study allosteric regulation in several other CTKs, we needed to ﬁnd expression
systems that could give enough yield in order to carry out biochemical assays as well as
conformational studies by SAXS. Altough we were able to use E. coli expression for the Abl
kinase study, some of the selected kinases were not well expressed in E. coli. This prompted us
to develop another fast expression system using insect cells transfection. We showed that we
could express the Zap70 kinase domain using this system. Thus, it might be possible to use S2
cells transfection as a fast replacement strategy for kinases that are difﬁcult to purify from E.
coli. New trials are ongoing to conﬁrm the possible expression of other CTKs. This includes
the use of constitutive as well as inducible expression vectors and co-expression with the YopH
phosphatase. It is now clear that each kinase will require a speciﬁc expression system and the
general strategy used for the Abl kinase is not applicable to most of the others CTKs.
3.4.2 Activation loop autophosphorylation: a focus on the Btk kinase
Preliminary studies of CTKs in transfected HEK293 cells led us to the observation that some ki-
nases showed strong activation loop phosphorylation dependence on their protein-interacting
domains (PIDs). Btk and Brk showed elevated activation loop phosphorylation only when one
or more PIDs were present. Src family kinases such as Hck showed activation loop phospho-
rylation even in the absence of any PIDs in line with the rapid autophosphorylation of the
Src KD already observed in vitro when using a generic phospho-tyrosine antibody (Seeliger
et al., 2007). These results could be potentially indicating other type of positive allosteric
interaction between the PIDs and kinase domains of other kinases than Abl. This study has to
be completed by analyzing the effects of point mutations in the SH2 or SH3 disrupting their
canonical functions to really conﬁrm allosteric roles for the PIDs in activating kinase activity
and autophosphorylation ability. This will also help mapping the possible kinase families
that show dependence on their PIDs for kinase activation. We show here that the Btk and Brk
could be potentially regulated allosterically while the Src family might be independent of such
mechanisms.
Further evaluation of the Btk kinase has led to several interesting observations. Using mutants
disrupting the SH2 phospho-tyr binding did not impair activation loop phosphorylation of
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Btk SH2-KD construct in transfected HEK293 cells. This is a strong indication that other
mechanisms might be implied and that the SH2 could have non-canonical roles in activating
Btk as observed for Abl. In vitro autophosphorylation of Btk KD, SH2-KD and SH3-SH2-
KD conﬁrmed a positive role of the SH2 but adding the SH3 reversed the activation loop
autophosphorylation ability. This is in line with the recent structure of the Btk SH3-SH2-KD
unit showing an autoinhibited conformation similar to the Src and Abl SH3-SH2-KD modules
(Wang et al., 2015). The activating effect of the SH2 for Btk activation loop autophosphorylation
was drastic while almost no differences were observed in catalytic activity comparing Btk
KD and SH2-KD. This suprising result was in discrepancy with the recent study of Wang
et al. (2015) where Btk KD showed very low activity and the SH2-KD activity was extensively
higher. It is important to note that the peptide used in our assay, despite not being a natural
substrate of the Btk kinase, harbours only one phosphorylatable tyrosine. In the case of
Wang et al. (2015), the peptide was a natural sequence of PLCγ which has two tyrosines,
making conclusions difﬁcult as the observed increase in activity could be due to processive
phosphorylation when the SH2 domain is present. Activation loop phosphorylation of Btk KD
has been shown to drastically increase its catalytic activity (Lin et al., 2009). It is likely that the
strong autophosphorylation of Btk SH2-KD in the activation loop might increase its catalytic
activity to higher extents that the KD only and more experiments using deﬁcient activation
loop mutant and pre-phosphorylated proteins are ongoing.
We observed a discrepancy between the autophosphorylation rate of Btk SH3-SH2-KD in
solution and in transfected HEK293. While the puriﬁed construct was unable to undergo
fast autophosphorylation, we observed strong phosphorylation of the activation loop when
transfected in HEK293 which was completely abrogated upon the R307G mutation in the SH2
phospho-tyrosine binding motif. One explanation could be an opening of the Btk SH3-SH2-
KD closed conformation in cells by SH2 binders (tyrosine-phosphorylated partners) which
have already been shown to open and activate Abl (Hantschel et al., 2003). This would be
prevented by the R307G mutation in the SH2 which would keep the conformation closed and
explain the low phosphorylation level of the SH3-SH2-KD R307G construct. Binding of other
tyrosine kinases to the Btk SH3-SH2-KD construct could also induce trans-phosphorylation
of the activation loop by those kinases, hence the increase phosphorylation levels. Indeed it
is known that the activation loop of Btk is also trans-phosphorylated by other kinases such
as Src kinase family members. Still, it is clear that the Btk kinase can autophosphorylate its
activation loop and that trans-phosphorylation by its partners may not be the only responsible
mechanisms for full Btk activation. Further studies are ongoing to understand the mechanism
of Btk activation.
Loss of function mutations in Btk are the leading cause of X-linked agammaglobulinemia
(XLA). The Btk SH2 domain is often mutated in XLA and more than 40 residues are found to be
mutated among the 96 residues constituing the domain. Many of these mutations have been
studied in vitro and it has been shown that even if some affect the canonical function of the SH2
domain (decreased binding afﬁnity for phosphotyrosines) many have yet to be characterized.
Surprisingly, no missense mutations have been observed in the SH3 (BtkBASE, last update in
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november 2015), altough this domain is known to harbour an autophosphorylation site (Y223)
with a role that still remains elusive. In this study, we hope to ﬁnd possible Btk SH2 mutations
preventing autophosphorylation of the activation loop or decreasing overall kinase activity
that would be implied in allosteric interactions with the kinase.
3.4.3 General strategies for studying positive allosteric mechanisms
With this study we would like to assess the strategies that one might use to understand al-
losteric regulation of CTKs both in solution but also in a cellular context. Thanks to the
knowledge we gathered with the in-depth study of the Abl SH2-KD interface allosteric regula-
tion as well as preliminary studies of the Btk kinase, we identiﬁed several critical points that
one might adress when studying CTKs regulation.
It is critical to correctly separate kinase activity and auto/trans-phosphorylation ability. De-
creased autophosphorylation ability might not always be due to an impaired kinase activity,
but could also be explained by more exquisite mechanisms such as sterical hindrance and
conformational changes. The use of generic anti-phosphotyrosine antibodies such as 4G10 to
compare kinase activity of constructs harbouring deletion of whole domains is not a viable
solution. Indeed, deletion of such domains also means deletion of potential phosphorylated
tyrosines, which in turns will lead to a decreased phospho-signal simply because critical
tyrosines are absent. That is why we propose to use the activation loop phosphorylation
status as a critical site to understand allosteric regulation. We observed that activation loop
phosphorylation is for some CTKs highly dependent on the presence of PIDs. Whether this
might indicate any allosteric activation effects need to be identiﬁed using mutational studies
to prevent canonical functions of PIDs.
Analyzing activation loop phosphorylation status of CTKs contructs might provide a relatively
quick method to detect potential CTKs that show allosteric activating effects of their PIDs.
Overall, combining conformational SAXS studies, kinase activity assays, as well as harnessing
the activation loop phosphorylation for each CTK might be a good way to start screening for
potential PID-kinase interactions. As each CTK is only expressed in some types of cells, it is
important that further studies will imply cell lines that are relevant for the disease-related
CTKs such as using B-cell cell lines for Btk. The use of HEK293 cells provides a quick way
to detect interesting mechanisms but would not be a good environment to understand how
allosteric regulation can affect downstream effectors phosphorylation, as most effectors of
Btk are for example absent in HEK293 cells. Using monobodies binding PIDs such as SH2 and
SH3 and point mutations in PIDs will help to discover new hotspots in CTKs that can be later
on targeted using small molecules (ﬁgure 3.3).
We are studying the conformation of several CTKs that we could express in E. coli including
all possible constructs (KD to full-length) for Btk and Csk, the Fes SH2-KD and Src KD and
SH3-SH2-KD. This ﬁrst trial gave us a good base to know which conditions should be used for
each construct and we should obtain SAXS reconstructions for some CTKs during this year.
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Figure 3.3 – Model of positive allosteric regulation via protein-interacting domains. Once
activated, cytoplasmic tyrosine kinases active conformation is maintained through allosteric
interactions between the kinase domain (blue) and PIDs (green). Preventing this interaction
with a drug (purple) will induce a perturbe active conformation unable to correctly phospho-
rylate downstream targets. PID: Protein-interacting domain.
3.4.4 Targeting allosteric sites in kinases: combination therapies
Btk, essential component of the early BCR signaling pathway, is a validated cancer target
in some type of hematoligcal malignancies. Ibrutinib (PCI-32765) is a Btk inhibitor that
binds covalently to cysteine 481 in Btk ATP-binding site (irreversible inhibition). It has shown
remarkable clinical response in chronic lymphocytic leukema and mantle cell lymphoma, and
has been FDA-approved for the treatments of these diseases. However, more than 5% of the
patients have progressed after a 1 year of follow-up (Woyach et al., 2014). Recently, studies
have shown that most of these patients had the cysteine 481 mutated to a serine (Cheng et al.,
2015), keeping the Btk kinase functional but rendering ibrutinib inhibition much less efﬁcient.
This is another example that a different strategy is needed for peculiar patients and targeting
new sites in Btk kinase domain or any other domains might be efﬁcient.
Most, if not all, classical ATP-competitions strategies are usually facing point mutations close
to the inhibitor binding sites rendering the inhibitor inefﬁcient. Similarly many suffer from
undesired selectivity proﬁles. Allosteric inhibition of kinases is a recent ﬁeld compared to
classical inhibition but it has evolved rapidly in the past few years since the approval of the
ﬁrst allosteric inhibitor on the market: trametinib. Trametinib is targeting the MEK kinase
family and showed good results and safety proﬁles, it was approved as a single agent therapy
for patients with the BRAF V600E mutated metastatic melanoma. Within 6 to 8 months
resistance appeared. Single-site mutations in the allosteric binding pocket and activation
loop of MEK1 have been identiﬁed in melanoma that inhibit the binding of allosteric MEK
inhibitors. Interestingly, a combination therapy with dabrafenib , an ATP-competitive inhibitor
targeting the upstream kinase BRAF was shown to signiﬁcantly improved survival of patients
compared to single-therapy with trametinib (Flaherty et al., 2012). Still, most patients relapse
after 9 to 11 months with this combination therapy mostly due to MAPK reactivation because
of BRAF ampliﬁcation or additional oncogenic mutation (Long et al., 2014). It is important to
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note that trametinib, despite being considered as an allosteric inhibitor, binds very close to
the ATP-binding site in a so-called "allosteric" pocket that needs speciﬁc orientation of the
activation loop. This important feature prevents to actually target the same kinase, namely
MEK, with both ATP-competitors and allosteric inhibitors.
Targeting of the same protein but at different sites has been recently achieved for the Abl
kinase. A combination therapy using ABL001, targeting the myristate binding pocket, and
Nilotinib, targeting the ATP-binding site, conducted by Novartis promoted a sustained tumor
regression for over 150 days in CML mice model (Wylie et al., 2014). Importantly, and on the
contrary to single agents dosing with both inhibitors, no resistance has been observed upon
combination therapy. These results showed that therapeutically relevant inhibition of Bcr–Abl
activity can be achieved by combining allosteric and ATP-competitive inhibitors and that
this can overcome resistance to either agent alone. These exciting results might prove that
combination therapy with allosteric agents might be a solution in certain type of cancers such
as CML. It remains still elusive if such combinations will work with other type of kinases and
we believe that using our strategies to understand CTKs allosteric regulation might help to
answer this question.
3.5 Concluding remarks and future perspectives
We presented evidence that mechanisms of Abl activation can be mirrored using pure re-
combinant proteins produced in bacteria. This approach enabled the discovery of a novel
mechanism that links the allosteric regulation of the SH2 domain to two critical phosphoryla-
tion events in the SH2-KD linker and in the activation loop and expanded our understanding
of Abl kinase activation. Using monobodies disrupting the Abl SH2-KD interface we have been
able to conﬁrm the therapeutic potential of targeting allosteric intramolecular interactions in
the Bcr-Abl oncogenic kinase. The monobodies could be further used to develop a screening
assay for inhibitors that would mimick their effects. The monobody-based screening assay
was robust and is further being improved.
Evidence of further allosteric activation is under investigation and interesting preliminary
results showed that the Btk kinase might also be positively inﬂuenced by its PIDs domains.
Although the ample availability of validated research tools, such as antibodies, kinase in-
hibitors and mutations, has accelerated the process, the proposed workﬂow and experimental
approaches will facilitate future quantitative analyses of allosteric regulatory mechanisms in
other tyrosine kinases.
Next generation technologies will be needed to identify complex regulatory interdomain com-
munications at the full-length level of CTKs. It will also be interesting to analyze the dynamic
binding of proteins/ligands that would alter the intramolecular interactions of certain CTKs
such as SH2/SH3 binders. We hope that our structural and functional studies of multidomain
constructs of CTKs will show the diversity of possible positive allosteric interactions as well as
potential ways to target them.
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4.1 Abl protein expression, puriﬁcation and biophysical analysis
4.1.1 Cloning of Abl constructs
Numbering of the isoform 1b of the human ABL1 gene is used in the manuscript. cDNAs
encoding for human ABL1 (Abl kinase domain (KD): residues 248-534, Abl SH2-kinase domain
(SH2-KD): 138-534) were cloned into the pET-21d vector using NheI and XhoI restriction sites.
The 2xMyc-SBP tag was cloned into the XhoI and SalI site of pET-21d, adding the tag at the
C-terminus of Abl SH2-KD cDNA. All point mutations were added using the Quickchange
site-directed mutagenesis kit (Stratagene).
4.1.2 Abl co-expression with YopH phosphatase and puriﬁcation
BL21(DE3) E.coli cells were transformed with both plasmids encoding for the desired Abl
construct as well as a plasmid harbouring the YopH phosphatase. The transformed cells were
grown in Terriﬁc Broth medium until the culture reached an OD600nm of 1.2. After adding 1
mM of IPTG, protein expression was carried out at 18°C. After 16 hours, cells were harvested
and the pellet solubilized in resuspension buffer (500 mM NaCl, 50 mM Tris-HCl pH 7.5,
5% Glycerol, 25 mM imidazole and 1 mM DTT). Cells were lysed by homogenization using
Avestin Emulsiﬂex C3 homogenizer with 3 cycles of lysis at 15.000 psi. Lysates were clariﬁed
by centrifugation at 20.000 rpm for 30 minutes. The soluble fraction was applied to a 5 mL
HisTrapFF crude colum and the protein eluted with a gradient (0-100%) of resuspension buffer
+ 500 mM imizadole. The eluted peak fractions were pooled and applied to a subsequent
desalting column (HiPrep 26/60). Finally, the desalted sample was puriﬁed over a monoQ
5/50GL. Each puriﬁcation step was followed by coomassie staining.
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4.1.3 Multi-angle light scattering analysis of puriﬁed Abl constructs
Multi-angle light scattering was used to probe for protein quality and oligomerization states.
All measurements were perfomed at RT using DAWN HELLIOS multi-angle light scattering
detector (Wyatt Technology Corp, Santa Barbara CA) online with a size exclusion chromatog-
raphy column (SEC). 80 μL (0.5 mg/mL) of puriﬁed recombinant protein was injected onto a
Superdex 75 HR10/30 column (GE Healthcare) in SEC buffer (25 mM Tris-HCl pH 7.5, 100 mM
NaCl, 5% glycerol, 1 mM DTT) and eluted at a ﬂow rate of 0.5 mL/min. Absolute molecular
weights and homogeneity were determined using ASTRA version 5.3 from Wyatt Technologies.
4.1.4 Circular dichroism spectroscopy
The Far-UV spectrums (195-205 nm) of Abl SH2-KD WT and I164E were carried out in 25 mM
phosphate buffer pH 7 at room temperature using a 0.1 cm quartz cell and Jasco J-815 CD
Spectrometer equipped with a thermostated cell holder. Data was acquired at a step size of
0.5 nm and bandwith of 1 nm. 3 scan records was used for each protein to generate the data
reported in units of mean molar ellipticity per residue.
4.1.5 Small-Angle X-ray scattering
Synchrotron Small Angle X-ray Scattering (SAXS) data were collected at EMBL P12 beamline
(DESY, Hamburg) and recorded at 10°C using PILATUS 1M pixel dectetor (DECTRIS) at a
sample-detector distance of 2.7 m and a wavelength of 1.2 Å. This setup covers a range of
momentum transfer of 0.0005 < s < 0.6 Å−1 (s = 4πsin(θ)/λ, where 2θ is the scattering angle).
A robotic sample changer was used and the samples were measured in a concentration range
from 4.5 to 0.6 mg/mL for WT and 1.3 to 0.4 mg/mL for the I164E mutant. Initial data process-
ing and reduction were performed using an automatic pipeline and theoritical extrapolation
to inﬁnite dilution. For the calculation of the forward scattering I (0) and the radius of gyration
(Rg ), the Guinier approximation implemented in PRIMUS was used, assuming that at very
small angles (s < 1.3/Rg ) the intensity is represented as I (s) = I (0)∗ exp(−(sRg )2/3). The
pair-distance distribution function P(r) was evaluated with GNOM and consecutively the
maximum particle dimension (Dmax) as well as Rg were estimated. The Porod volume was
computed using the Porod invariant, and the molecular mass estimated. Ab initio models
were computed with DAMMIF, using low resolution data in the range of 0.012 Å−1 < s < 0.200
Å−1. The algorithm constructs bead models yielding a scattering proﬁle with the lowest pos-
sible discrepancy (χ) to the experimental data while keeping beads interconnected and the
model compact. Twenty independent ab initio reconsutrctions were performed and then
averaged using DAMAVER, which also provides a value of normalized spatial discrepancy
(NSD), representing a measure of similarity among different models. Model superimposi-
tion was computed using the program SUPCOMB. Rigid Body Modelling were performed
using the software BUNCH. Flexibility was assessed with the software Ensemble Optimization
Method 2.0 which assumes coexistence of a range of conformations in solution for which an
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average scattering intensity ﬁts the experimental SAXS data. Using EOM 2.0, a pool of 10.000
independent models is initally generated. The theoritical scattering curve is automatically
computed for each model in the pool by using CRYSOL. Afterwards, a genetic algorithm (GA) is
employed to selected ensembles, randomly distributed in term of size from 5 to 20 coformers,
by calculating the average theoritical proﬁles and ﬁtting them to the experimental SAXS data.
The GA is hence repeated 100 times, and the ensemble with the lowest discrepancy is reported
as the best solution out of 100 ﬁnal ensembles.
4.2 Abl kinase assays and autophosphorylation
4.2.1 In vitro kinase assays
1 ng of recombinant protein, 75 μM ATP, 7 μCi γ−32P-ATP was incubated with an optimal Abl
substrate sequence carying an N-terminal biotin (biotin-GGEAIYAAPFKK) in kinase assay
buffer (20 mM Tris-HCl pH 7.5, 5 mM MgCl2, 1 mM DTT, 10μM BSA) for 12 minutes at room
temperature in a ﬁnal assay volume of 20 μL. Peptide concentrations ranged from 3.125 μM to
100μM. The terminated reaction (10μL 7.5 M guanidinhydrochlorid) was spotted onto a SAM2
Biotin Capture membrane (Promega) and further treated according to the instructions of the
manufacturer. For monobodies co-incubation, recombinant kinase was ﬁrst pre-incubated
with selected monobodies at various concentrations for 10 minutes at room temeperature
before starting the reaction.
4.2.2 Mapping of Abl autophosphorylation sites
Recombinant Abl SH2-KD was incubated at 0.3 mg/mL in Tris 25 mM pH 7.5, 10 mM MgCl2,
1 mM DTT, 300 μM ATP for 2 hours at room temperature. Unphosphorylated Abl SH2-KD
sample was also incubated in similar conditions with the omission of ATP, and used as a
control during mass spetrometry analysis.
In gel digestion
Samples were separated by SDS-PAGE and Coomassie stained bands were In-Gel digested.
Bands of interest were excised, reduced in 10 mM DTE, 50 mM AB and then alkylated in 55
mM Iodoacetamide, 50 mM AB. After a last washing step, gel extracts were digested with either
MS Grade Trypsin, Endoproteinase GluC or Chymotrypsin over-night. Resulting peptides were
ﬁnally extracted using a high organic containing solvent and dried by vacuum centrifugation
prior to LC-MS2 measurements or Phosphopeptides enrichment.
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Phosphopeptides enrichment
Around 90% of the extracted peptide amounts were used for Phosphopeptides enrichment
step while the remaining 10% was used for sample identiﬁcation. Titanium Dioxide afﬁnity
principle was used for the enrichment using home-made titania tips (based on Thingholm and
Larsen 2009). After having equilibrated the tips with 0.75% TFA, 60% Acetonitrile, 300mg/ml
Lactic acid (named solution A), dried samples were resuspended in this very same solution
and loaded on tips. A ﬁrst washing step in solution A was performed followed by a second
one with 0.1% TFA, 80% Acetonitrile. A two-step elution was ﬁnally performed ﬁrst with 0.5%
Ammonium hydroxide and then with 5% Piperidine. Samples were acidiﬁed and dried down
prior to LC-MS2 measurements.
Mass spectrometry measurements
Dried samples were resuspended in 0.1% TFA and separated by C18 Reverse Phase nano UPLC
using a Dionex Ultimate 3000 RSLC system (Thermo Fischer Scientiﬁc) on line connected to
an Orbitrap Elite Mass Spectrometer (Thermo Fischer Scientiﬁc). Samples were ﬁrst trapped
on a home-made capillary C18 pre-column and then separated on a C18 capillary column
(Nikkyo Technos Co; Magic AQ C18; 3μm-100Å; 15cm x 75μm ID) at 250nl/min. over a 90min.
biphasic gradient ranging from 99% A (2% ACN, 0.1% FA) to 90% B (90% ACN, 0.1% FA). Data-
Dependent mode was used for MS acquisitions were the 20 most intense parent ions were
selected for subsequent fragmentation by CID and then excluded for 40 seconds. A Potential
Phosphopeptides m/z inclusion list was also generated and used to maximize detection
chances.
4.2.3 Abl autophosphorylation assays
Abl autophosphorylation assays were carried out with 265 nM of recombinant Abl proteins
in 20 mM Tris-HCl pH 7.5, 5 mM MgCl2, 1 mM DTT, 300 μM ATP in a total volume of 150
μL. Reactions were stopped at desired time points by adding 50 μL of 2X SDS-PAGE sample
buffer, 400 ng (30% of the total reaction volume) of proteins were dot blotted on a nitrocel-
lulose membrane using the BioDot Appartus (Bio-Rad) system following the manufacturer’s
recommendations. Total phosphotyrosine (4G10, Millipore), pY245 (2868S, Cell Signaling) or
pY412 (2865S, Cell Signaling) levels were quantiﬁed using the Li-cor Odyssey imaging system
and normalized for total Abl protein levels (Penta-His antibody, Qiagen, co-incubated with
the phosphotyrosine antibody). Abl proteins incubated with no ATP were used as background
and subtracted before normalizing values.
4.2.4 Abl transphosphorylation assays
Pairs of active an catalytically-deﬁcient KD and SH2-KD protein were mixed in a 1:1 molar ratio
at 265 nM ﬁnal concentration in 50 μL volume in 20 mM Tris-HCl pH 7.5, 5 mM MgCl2, 1 mM
66
4.3. HEK293 cell transfections
DTT, 300 μM ATP. Reactions were stopped at desired time points by adding 50 μL of 2X SDS-
PAGE sample buffer. 100 ng of protein were resolved on a 12% SDS-PAGE gel, transferred onto a
nitrocellulosemembrane by semidry electroblotting and incubatedwith total phosphotyrosine
(4G10, millipore), pY245 (2868S, Cell Signalling) or pY412 (2865S, Cell Signalling) antibodies
mixed with a Penta-His antibody (Qiagen). Phosphorylation levels were quantiﬁed using
the Li-Cor Odyssey imagin system and normalized for total Abl protein levels, Abl proteins
incubated with no ATP were used as background and substracted before normalizing values.
Abl KD/SH2-KD-drug complexes were obtained by incubating the protein with 3-fold molar
excess of imatinib or dasatinib (Symansis) for 10 minutes at room temperature, followed by
extensive dialysis against 150 mM NaCl, 20 mM Tris-HCl pH 7.5, 1 mM DTT, 5% glycerol to
remove the free drug. The ﬁnal dialized proteins were used as substrates for the assay.
4.3 HEK293 cell transfections
HEK293 cells were cultured in DMEM medium supplemented with 10% FCS and 1% peni-
cillin/streptomycin. Cells were co-transfected with Abl PP (Barila and Superti-Furga, 1998) or
Bcr-Abl and 6xMyc tagged monobodies expression vectors (pSGT vector for Abl and Bcr-Abl
and pCS2-gateway vectors for monobodies) using the Polyfect transfection reagent according
to the manufacturer’s instructions. 48 hours after transfection, cells were harvested and lysed
in IP buffer (50 mM Tris-Hcl pH 7.5, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 5 mM EGTA, 1 mM
orthovanadate, 1 mM PMSF, 10 mg/mL TPCK and protease cocktail inhibitor from Roche) and
cleared by centrifugation at 14.000 rpm, 4°C for 10 minutes. Total protein concentration was
measured using Bradford assay (Bio-rad; 500-0006).
4.4 Western blotting, immunoprecipitation and antibodies
4.4.1 Western blotting analysis and antibodies
Immunoblotting analysis 100 μg of cellular lysates were used. Samples were seperated by
SDS-PAGE and then transferred onto a nitrocellulose membrane (Whatmann, Protran BA85,
GE healthcare) with a semi-dry blotting system (Hoefer Scientiﬁc Semi-phor TE70). Membrane
and Whatman papers were pre-soaked in Western Blot buffer (25 mM Tris, 192 mM Glycine,
10% Glycine, 10% (v/v) methanol). After blotting for 1.5 hours at 0.075 mA/cm2 the membrane
was blocked with blocking solution according to the antibodies’s manufacturer instructions.
Primary antibodies were incubated overnight at 4°C. The next day, membrane was washed
three times 5 minutes with TBS-T or PBS-T (0.1% Tween 20). Following the washing, the
primary antibody was detected with IRDye680 and IRDye800-coupled antimouse or antirab-
bit antibody or HRP-conjugated IgG antibodies diluted in the washing buffer. Secondary
antibodies were washed away (3 times, 5 minutes in washing buffer).
The following antibodies were used: total phosphotyrosine (4G10, millipore), anti-Abl (A5844,
sigma), pY412 (2865S, Cell Signalling), anti-myc-IRdye800 (600-432-381, Rockland), IRdye680
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and IRdye800-coupled anti mouse (Li-cor, 926-32210) and anti-rabbit (Rockland, 611-732-
127), HRP conjugated anti-mouse (Jackson ImmunoResearch, 115-035-003), anti-rabbit (Jack-
son Immunoresearch, 111-035-003). ECL prime detection reagent was used to detect HRP-
conjugated antibodies (GE healthcare, RPN2232).
4.4.2 Abl immunoprecipitation
1 mg of total protein was used for immunoprecipitation from HEK293 cells lysates. The
required volume of cell lysate was calculated and volume was added up to 1 mL with IP buffer.
Home-made anti-Abl antibody was added to each IP sample and incubated for 3 hours on
rotating wheel at 4°C. 50 μL of Protein G sepharose (GE Healthcare, 17-0618-01) were added to
each sample and incubated 1 hour on rotating wheel at 4°C. Subsequently, beads were washed
3 times with IP buffer. During the ﬁnal wash, 20% of IP were spared to detected bait protein.
Beads were ﬁnally boiled in laemmli buffer for 5 minutes at 95°C.
4.5 Expression and puriﬁcation of recombinant monobodies
Monobodies were produced with an N-terminal 10xHis-FLAG tag using the pHFT2 vectors.
Proteins were expressed in E. coli BL21(DE3). After bacterial transformation, P0.5G medium
was inoculated and the preculture grown overnight at 37°C. 1 mL of the P0.5G preculture was
used to innoculate 1 L of auto-induction medium (Formedium, LB-broth based with trace
elements). The culture was grown at 37°C and after 4 hours the temperature decreased to 18°C
for 18 hours. Bacteria were harvested and lysed similarly as in 4.1.2. Protein were puriﬁed to
apparant homegeneity using Ni-afﬁnity sepharose beads (GE healthcare). Final samples were
puriﬁed using gel ﬁltration Superdex 75 16/60 column and the corresponding peak fractions
pooled and purity veriﬁed on coomassie staining.
4.6 Retroviral transduction and FACS analysis of K562 cells express-
ing monobodies
K562 cells were cultured inRPMImediumsupplementedwith 10%FCS and 1%penicillin/strep-
tomycin. K562 cells stably-expressing N-TAP fused monobodies (AS25, AS27, HA4 and HA
Y87A) were generated by retroviral gene transfer as described previously in (Wojcik et al.,
2010). For six consecutive days starting 24 hours after the second retroviral infection of the
target K562 cells and every 24 hours, aliquots of 106 cells were removed from the culture and
were analyzed by ﬂow cytometry (Accuri C6, BD Biosciences). Cells were analyzed for GFP
expression (co-expressed with TAP-tagged monobodies) and in parallel stained with Annexin
V Cy5 (BD PharmingenTM, 559933) and 7-AAD (BD PharmingenTM, 559925).
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4.7 Cytoplasmic tyrosine kinase characterization
4.7.1 Recombinant puriﬁcation from E. coli
Most of the CTKs were expressed in a similar way to Abl (see Section 4.1.2) except for the Btk
kinase constructs that were co-expressed with YopH phosphatase as well as the GroEL/GroES
co-chaperones sytem as described in (Wang et al., 2015).
4.7.2 Expression and puriﬁcation trial from S2 insect cells
The human SH2-KD D382N of Abl1b isoform (S248 to V534) and KD of Zap70 (M327 to G606)
harboring a C-terminus 6x-His-tag were cloned into the plEx-X plasmid. S2 cells were grown
in suspension in SF900 II SFM medium (Thermo Scientiﬁc, 10902-096) at 28°C (180 rpm,
0% C02, 80 % humidity). On the day of transfection, the cells were centrifuged (300 rpm, 5
min) and re-suspended in culture media in 35% of the intended volume at a density of 5*106
cells/mL. Plasmid DNA (600 μg for 200 mL culture) was mixed with 2 mg of PEI (1 mg/mL)
and incubated at room temperature for 10 minutes. The mixture was added to the cells and
the culture incubated at 28°C. After 45 minutes, culture medium was added to the cells in a
ﬁnal volume of 200 mL.
3 days after transfection, the cells were harvested at 500 rpm during 15 minutes and the pellet
re-suspended in 20 mL of lysis buffer A (50 mM Tris pH 7.5, 500 mM NaCl, 5% glycerol, 5 mM
β-mercaptoethanol, 1 mM PSMF (Roche, Basel, Switzerland) and Roche protease inhibitor
(Roche)). Cells were lysed using 3 rounds of 5 minutes sonication at 30% amplitude with
10 sec on/off cycles on ice. Lysed cells were spun down at 18000 rpm for 30 min, and the
supernatants were ﬁltered at 0.45 μm. The supernatants were incubated with 2 mL of pre-
equilibrated Ni-NTA beads (in lysis buffer) for 2 h at 4 °C. Beads were washed with 30 column
volumes (60 mL) of washing buffer (Lysis buffer A + 25 mM imidazole). Proteins were eluted
with 5 column volumes of elution buffer (Lysis buffer A + 500 mM imidazole), and extensively
dialyzed against 50 mM Tris pH 7.5, 150 mM NaCl, 5% glycerol, 1 mM DTT buffer. Sample
purity was veriﬁed by Coomassie Blue staining.
For measuring zap70 KD kinase activity, 50 ng of recombinant tyrosine kinase, 75 μM ATP,
7 μCi γ-32P-ATP was incubated with a peptide with 200 μM of an optimal Abl substrate in
kinase assay buffer (20 mM Tris-HCl pH 7.5, 5 mM MgCl2, 1 mM DTT) for 30 minutes at RT in a
ﬁnal assay volume of 20 μL. The terminated reaction (10 μL 7.5 M guanidinhydrochlorid) was
spotted onto a SAM2 Biotin Capture membrane (Promega, Madison, WI) and further treated
according to the instructions of the manufacturer.
4.7.3 HEK293 cells transfections
All kinase constructs presented in table 2.4) were cloned in pCS2-gateway plasmid containing
an N-terminal Myc tag. For each kinase several plasmid amounts were tried in order to obtain
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similar expression levels between the constructs. HEK293 cells were transfected as described
in Section 4.3.
The following antibodies were used: anti-pY551 Btk (BD Biosciences, 558034), anti-pY416
Src family (Cell Signaling, 2101S) , anti-pY342 Brk (Millipore, 09-144), anti-pY319 Zap70 (Cell
signaling, 2701) and anti-myc-IRdye800 (600-432-381, Rockland).
4.7.4 Fluorescence polarization assay with Btk SH2 domain
Btk SH2 mutants were incubated at several concentrations with 250 nM of FITC-labeled
pYEEI peptide in Tris 25 mM pH 7.4, 50 mM NaCl, 2 mM DTT. Fluorescence polarization was
then measured using the SpectraMax M5 with excitation at 485 nm and emission at 530 nm
(molecular devices) in a 96 well black-plate (Greiner, 784-900).
4.7.5 Btk autophosphorylation assay
Recombinant Btk kinase constructs were incubated in Tris 25 mM pH 7.5, 150 mM NaCl,
5% glycerol, 1 mM ATP, 20 mM MgCl2, 1 mM DTT at 1 μM concentration. Reactions were
stopped at desired time points by adding 2X Laemmli buffer to each tube. Samples were
immunoblotted on a nitrocellulose membrane. The following antibodies were used : anti-
Btk kinase (Pierce, PA5-27392) and anti-pY551 Btk (BD Biosciences, 558034). Btk proteins
incubated with no ATP were used as background and subtracted before normalizing values.
4.8 Screening assays
4.8.1 Acrylodan labeling and measurements
Abl acrylodan protein mutants were puriﬁed as in Section 4.1.2. In total 8 cysteines mutant
were used. Abl SH2-KD C324V C349S was used a control (no cysteine in SH2) and the following
mutants were labeled: SH2-KD C324V C349S E187C, SH2-KD C324V C349S L159C, SH2-KD
C324V C349S T231C as well as their corresponding I164E versions. Kinase mutants activity
was measured as in Section 4.2.1 except using a ﬁx Abl peptide concentration of 75 μM.
Before labeling, DTT was removed from puriﬁed proteins using PD10-desalting columns (GE
healthcare). Acrylodan was obtained from Thermo-Fisher (A-433) and resuspended in DMSO
at 10 mM stock concentration. Labeling was carried out in HEPES 25 mM pH 7, 200 mM NaCl,
5% Glycerol, at 4°C overnight while shaking in a rotating wheel. Puriﬁed proteins were co-
incubated in 1:3 to 1:10 molar ratio with acrylodan, with protein concentration ranging from
20 to 50 μM. After labeling, reaction was quenched by adding 1 mM DTT and free acrylodan
removed using PD-10 columns or extensive dialysis against labeling buffer.
Fluorescent measurements were carried out using TECAN SAFIRE 2 in 384 small-volume black
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Greiner plates (low-binding, 784 900). 15 μL of labeled proteins were added to each well at
various protein concentrations (5 to 20 μM). Acrylodan-conjugated proteins were then excited
at 380 nm and emmitted ﬂuorescence measured in between 400 and 550 nm. For monobodies
co-incubation assays the protein mutants were incubated with increasing concentrations of
AS25 for 5 minutes at room temperature and then acylodan ﬂuorescence was measured. A
unrelated monobody (Nsa5) was also used as a control.
4.8.2 HTRF measurements of AS25-SH2 complexes
All tagged proteins were puriﬁed in Tris buffer 25 mM pH 7.5, 100 mM NaCl,1 mM DTT and
5% glycerol. 5 μL of tagged AS25, tagged Abl SH2, Anti-tag 1-donor (Terbium cryptate) and
Anti-tag 2-acceptor (d2 or XL665) were mixed and added into a 384 low-volume white Greiner
plate (784075). 4 background controls were measured: A cryptate blank (10 μL of buffer, 5 μL
of detection buffer and 5 μL of Terbium-cryptate), a negative (10 μL of buffer, 5 μL of both
donor and acceptor), a negative containing all reagents and only tagged Abl SH2, a negative
containing all reagents and only tagged AS25. The following reagents were used (Cisbio):
61HI2TLA, 61HISDLA, 61HISXLA, 61GSTTLA, 61GSTDLA, 61GSTXLA, 61FG2TLA, 61FG2DLA,
61FG2XLA, 610SATLA, 610SADLA, 610SAXLA.
Samples were measured using the PHERAstar FS with an excitation wavelength set at 337
nm and emission measured simultaneously at 665 and 620 nm (delay time 60 μs, integration
time 400 μs, 300 ﬂashes). HTRF signal, Signal-to-noise ratio and assay window are deﬁned as
followed:
HTRF signal = 665 nm620 nm x 10.000.
Signal-to-noise ratio = HTRF si gnal
assay
HTRF si gnalnegati ve
Assay window = HTRF si gnal
assay
HTRF si gnaluntagged AS25
Where 665 nm and 620 nm are the ﬂuorescence emission intensities at the respective values
(relative ﬂuorescence unit), HTRF si gnal assay is the signal obtained when both tagged AS25
and Abl SH2 are added, HTRF si gnalnegati ve is the highest HTRF value obtained from the
4 background controls measured, HTRF si gnaluntagged AS25 is the signal obtained after
addition of cleaved (untagged) AS25 added to the assay sample at 100-fold excess over tagged
AS25 (overnight).
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